0001214659-23-007834.txt : 20230525 0001214659-23-007834.hdr.sgml : 20230525 20230525172538 ACCESSION NUMBER: 0001214659-23-007834 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20230525 DATE AS OF CHANGE: 20230525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biodexa Pharmaceuticals Plc CENTRAL INDEX KEY: 0001643918 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-267932 FILM NUMBER: 23962109 BUSINESS ADDRESS: STREET 1: 1 CASPIAN POINT STREET 2: CASPIAN WAY CITY: CARDIFF STATE: X0 ZIP: CF10 4DQ BUSINESS PHONE: 44 (0)1235 888300 MAIL ADDRESS: STREET 1: 1 CASPIAN POINT STREET 2: CASPIAN WAY CITY: CARDIFF STATE: X0 ZIP: CF10 4DQ FORMER COMPANY: FORMER CONFORMED NAME: Midatech Pharma Plc DATE OF NAME CHANGE: 20150602 424B5 1 r524231424b5.htm

Filed pursuant to Rule 424(b)(5)
Registration No.: 333-267932

PROSPECTUS SUPPLEMENT
(to Prospectus dated October 26, 2022)

BIODEXA PHARMACEUTICALS PLC

22,135,922 American Depositary Shares
Representing 110,679,610 Ordinary Shares

We are offering 22,135,922 of our American Depositary Shares, or Depositary Shares, at a price of $0.15 per Depositary Share pursuant to this prospectus supplement, or the Registered Depositary Shares. Each Depositary Share represents 5 of our ordinary shares, nominal value £0.02p per share, or ordinary shares.

In a private placement, or the Private Placement, we will also issue to the purchasers in this offering (i) Depositary Share purchase warrants exercisable for an aggregate of 33,203,883 Depositary Shares, or the Series C Warrants and (ii) Depositary Share purchase warrants exercisable for an aggregate of 22,135,922 Depositary Shares, or the Series D Warrants, and collectively with the Series C Warrants, the Warrants. The Warrants will be exercisable at an exercise price of $0.20 per Depositary Shares, subject to adjustments for certain dilutive equity issuances. The Warrants will become exercisable upon receipt of shareholder approval, or Shareholder Approval, to allot the Warrants, the Depositary Shares issuable upon the exercise of the Warrants, or the Warrant ADSs, and the ordinary shares underlying the Warrant ADSs, or the Warrant Shares offered in the Private Placement without triggering statutory preemptive rights under the laws of England and Wales. The Series C Warrants will expire one year from the initial exercise date and may be exercised on a cashless basis, subject to the satisfaction of payment of not less than the nominal value of the ordinary share under the provisions of the United Kingdom Companies Act of 2006, or the Companies Act. The Series D Warrants will expire five years from the initial exercise date. Six months after the issuance date of the Series D Warrants, if and only if there is no effective registration statement registering the applicable Depositary Shares, or no current prospectus available for such shares, the resale of the Depositary Shares issuable upon exercise of the Series D Warrants, the purchaser may exercise the Series D Warrants by means of a “cashless exercise, subject to the satisfaction of payment of not less than the nominal value of the ordinary share under the provisions of the Companies Act.” A holder of the Warrants may not exercise the Warrants if the holder, together with its affiliates, would beneficially own more than 4.99% or 9.99% (such amount to be determined at the option of the holder) of the number of ordinary shares outstanding immediately after giving effect to such exercise. The Warrants, the Warrant ADSs, and the Warrant Shares are not being registered under the Securities Act of 1933, as amended, or the Securities Act, pursuant to the registration statement of which this prospectus supplement and the accompanying base prospectus form a part, nor are such Warrants, Warrant ADSs and Warrant Shares being offered pursuant to such prospectus supplement and base prospectus. The Warrants are being offered pursuant to the exemption provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The Warrants are not, and will not be, listed for trading on any national securities exchange. Each investor will be an “accredited investor” (as such term is defined in Rule 501(a) under the Securities Act) or “qualified institutional buyer” (as such term is defined in Rule 144A under the Securities Act).

Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing price of Depositary Shares on the NASDAQ Capital Market on May 22, 2023 was $0.19.

We have engaged Ladenburg Thalmann & Co. Inc. to act as our exclusive placement agent, or the placement agent, in connection with the securities offered by this prospectus supplement and the accompanying prospectus. The placement agent has agreed to use its reasonable best efforts to sell the securities offered by this prospectus supplement and the accompanying prospectus. The placement agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay the placement agent the placement agent fees set forth in the table below, which assumes that we sell all of the securities we are offering.

The highest aggregate market value of our outstanding ordinary shares held by non-affiliates, or public float, was approximately $22,034,245, based on 96,679,412 of our ordinary shares outstanding, of which approximately 96,643,428 shares are held by non-affiliates, and a per share price of approximately $0.228, which represents one-fifth of $1.14, which was the price of our Depositary Shares on March 24, 2023, and which was the highest reported closing sale price of our Depositary Shares on the NASDAQ Capital Market, the principal market for our common equity, in the 60 days prior to May 23, 2023. As of the date of this prospectus supplement, we have sold or offered 98,493 Depositary Shares for aggregate gross proceeds of $393,973 pursuant to General Instruction I.B.5. of Form F-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement. As a result, we are eligible to offer and sell up to an aggregate of $7,213,424 of our Depositary Shares pursuant to General Instruction I.B5. of Form F-3.

______________________________

Investing in our securities involves risks. See “Risk Factors” beginning on page S-12 in this prospectus supplement and on page 4 of the accompanying prospectus and the documents incorporated by reference herein for a discussion of the factors you should carefully consider before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy of this prospectus. Any representation to the contrary is a criminal offense.

	Per Depositary Share		Total
Offering Price	$	0.15	$	3,320,388
Placement Agent Fees (1)	$	0.01	$	265,631
Proceeds to Us (before expenses)	$	0.14	$	3,054,757

(1)

We have also agreed to pay the placement agent a management fee of 1.0% of the aggregate gross proceeds in the offering, reimburse the placement agent for certain of its expenses and issue warrants to purchase Depositary Shares equal to 4.0% of the aggregate number of Depositary Shares issued in this offering, as described under the “Plan of Distribution” on page S-44 of this prospectus supplement.

(2)

The amount of the offering proceeds to us presented in this table does not include proceeds from the exercise of the Warrants for cash, if any.

Delivery of the Registered Depositary Shares is expected to be made on or about May 26, 2023, subject to the satisfaction of certain closing conditions.

______________________________

Ladenburg Thalmann

The date of this prospectus supplement is May 23, 2023

PROSPECTUS SUPPLEMENT

TABLE OF CONTENTS

ABOUT THIS PROSPECTUS SUPPLEMENT	S-1
WHERE YOU CAN FIND MORE INFORMATION	S-3
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE	S-4
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	S-5
PROSPECTUS SUPPLEMENT SUMMARY	S-6
RISK FACTORS	S-12
CAPITALIZATION	S-14
USE OF PROCEEDS	S-15
dividend policy	S-16
DILUTION	S-17
PRIVATE PLACEMENT TRANSACTION AND WARRANTS	S-18
DESCRIPTION OF OUR SHARE CAPITAL	S-19
description of american depositary shares	S-35
TAXATION	S-43
PLAN OF DISTRIBUTION	S-44
LEGAL MATTERS	S-46
EXPERTS	S-46
SERVICE OF PROCESS AND ENFORCEMENT OF JUDGMENTS	S-46

PROSPECTUS

TABLE OF CONTENTS

	Page

ABOUT THIS PROSPECTUS	1
PRESENTATION OF FINANCIAL INFORMATION AND OTHER DATA	1
PROSPECTUS SUMMARY	2
RISK FACTORS	4
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS	5
CAPITALIZATION	7
USE OF PROCEEDS	8
PLAN OF DISTRIBUTION	9
DESCRIPTION OF SHARE CAPITAL	11
DESCRIPTION OF WARRANTS	26
DESCRIPTION OF UNITS	27
DESCRIPTION OF AMERICAN DEPOSITARY SHARES	28
EXPENSES	34
LEGAL MATTERS	35
EXPERTS	35
ENFORCEMENT OF JUDGMENTS	35
WHERE YOU CAN FIND MORE INFORMATION	35
INCORPORATION OF DOCUMENTS BY REFERENCE	36

S-i

Table of Contents

ABOUT THIS PROSPECTUS SUPPLEMENT

This prospectus supplement and the accompanying prospectus relate to the offering of our Registered Depositary Shares. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the section of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision.

This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of the offering of the Registered Depositary Shares and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated by reference into the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to the combined document consisting of this prospectus supplement and the accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference into the accompanying prospectus that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement.

We are responsible only for the information contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not, and the placement agent has not, authorized anyone to provide you with different information or to make any representation other than those contained or incorporated by reference in this prospectus supplement. If any person provides you with different or inconsistent information, you should not rely on it. Neither we nor the placement agent take any responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.

We are not, and the placement agent is not, making an offer to sell or soliciting an offer to buy our Depositary Shares in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation.

You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates.

Unless the context specifically indicates otherwise, references in this prospectus supplement to “Biodexa Pharmaceuticals PLC,” “Biodexa,” “the Company,” “we,” “our,” “ours,” “us,” “the Group,” or similar terms refer to Biodexa Pharmaceuticals PLC and its subsidiaries.

We prepare our consolidated financial statements in British pounds sterling. In this prospectus supplement, references to “GBP,” “£,” “pence” or “p” are each to British pounds sterling (or units thereof), and references to “$,” “USD,” “US$” and “United States dollar” are each to the United States dollar.

On March 27, 2023, following shareholder approval, we effected a one-for-20 reverse split of our Ordinary Shares, and our Ordinary Shares began trading on AIM, a market operated by the London Stock Exchange plc, or AIM, on a split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock split. As a result of the reverse stock split, the number of issued and outstanding Ordinary Shares was reduced to 8,667,337 shares as of March 27, 2023. On March 24, 2023, our shareholders approved the cancellation of admission of our Ordinary Shares on AIM and this cancellation became effective on April 26, 2023.

S-1

Table of Contents

The change in the number of Ordinary Shares resulting from the reverse stock split and change in the number of Depositary Shares resulting from the change in ratio has been applied retroactively to all share and per share amounts presented in this prospectus, to the extent applicable.

S-2

Table of Contents

WHERE YOU CAN FIND MORE INFORMATION

We are subject to periodic reporting and other informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as applicable to foreign private issuers. Accordingly, we are required to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our “insiders” are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. The SEC maintains an Internet site that contains reports, proxy, information statements and other information regarding issuers at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.biodexapharma.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.

This prospectus supplement and the accompanying prospectus is part of a registration statement we filed with the SEC. This prospectus supplement omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus supplement concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC at the address listed above or from the SEC’s website.

S-3

Table of Contents

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC allows us to “incorporate by reference” the information we file with the SEC, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered part of this prospectus supplement from the date we file that document. Information that we file later with the SEC will automatically update and, where applicable, supersede any information contained in this prospectus supplement or incorporated by reference in this prospectus supplement. These documents contain important information about us and our financial condition.

This prospectus supplement incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed:

our Annual Report on Form 20-F for the year ended December 31, 2022, filed with the SEC on April 28, 2023 (the “Annual Report”) and Amendment No. 1 to our Annual Report filed with the SEC on May 5, 2023;

our Reports on Form 6-K and any amendments thereto furnished to the SEC on January 6, 2023, January 11, 2023, January 12, 2023, January 23, 2023, January 26, 2023, February 2, 2023, February 9, 2023, February 15, 2023, March 8, 2023, March 10, 2023, March 24, 2023, March 27, 2023, March 29, 2023 (both filings), March 30, 2023, April 4, 2023 (both filings), April 5, 2023, April 7, 2023, April 12, 2023, April 19, 2023, April 28, 2023, May 18, 2023, May 22, 2023 and May 24, 2023 that we incorporate by reference into this prospectus; and

the description of Depositary Shares representing our ordinary shares and our ordinary shares contained in our Registration Statement on Form 8-A originally filed with the SEC on December 2, 2015, and as amended on April 30, 2021, including any amendments or reports filed for the purpose of updating such description.

We will provide, without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request of such person, a copy of any or all of the documents incorporated or deemed to be incorporated herein by reference other than exhibits, unless such exhibits specifically are incorporated by reference into such documents or this document. Requests for such documents should be addressed in writing or by telephone to:

Biodexa Pharmaceuticals PLC
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ, United Kingdom
+44 29 2048 0180

S-4

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus supplement, the accompanying prospectus and the information incorporated herein by include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. All statements contained or incorporated by reference herein, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, other than statements of historical facts, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

S-5

Table of Contents

PROSPECTUS SUPPLEMENT SUMMARY

The following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus supplement. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus supplement and the accompanying base prospectus, including the documents incorporated by reference, which are described under “Where You Can Find Additional Information” and “Incorporation of Certain Information by Reference” in this prospectus supplement. You should also carefully consider the matters discussed in the section in this prospectus supplement entitled “Risk Factors.”

Biodexa Pharmaceuticals PLC

Overview

We are a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. Our lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma.

MTX110 is a liquid formulation of the histone deacetylase, or HDAC inhibitor, panobinostat. Our proprietary formulation enables delivery of the product via convection-enhanced delivery, or CED, at potentially chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and avoiding systemic toxicity.

Our clinical assets are supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of drugs through either sustained delivery (Q-Sphera^TM ), direct delivery (MidaSolve^TM ), or targeted delivery (MidaCore^TM ):

Our Q-Sphera platform: Our disruptive polymer microsphere microtechnology is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months.

Our MidaSolve platform: Our innovative nanosaccharide technology is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

Our MidaCore platform: Our leading-edge gold nanoparticle nanotechnology is used for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents.

Recent Developments

Proposed Transaction with Varian Biopharmaceuticals

On May 18, 2023, we signed a non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, Inc., a Delaware corporation, or Varian. Under the non-binding letter of intent, Varian will merge into an acquisition subsidiary of the Company and it is proposed that Varian equity and debt holders together, the Varian Securityholders, will receive 10 million of the Company’s Depositary Shares at close as initial consideration. On a pro forma basis, prior to the planned financing discussed below, Varian Securityholders will own approximately 34% of the post-acquisition Company. Varian Securityholders will receive up to a further 6 million Depositary Shares, issuable in two phases: 3 million upon the commencement of the first pivotal registration study of a Varian product and an additional 3 million upon the first U.S. Food and Drug Administration approval of a Varian product.

In addition, pursuant to the non-binding heads of terms, we plan to raise not less than $7.0 million, net of expenses, which will be used to fund VAR-101, a novel atypical protein kinase C iota inhibitor, through its Phase I proof-of-concept study that VAR-101 is targeting to commence in the first quarter of 2024.

The acquisition agreement is also expected to contain other customary conditions, including shareholder approval, and appropriate representations and warranties by the parties.

S-6

Table of Contents

February 2023 Private Placement

On February 15, 2023, we completed a private placement (the “February Private Placement”) with certain institutional investors, for the sale of up to an aggregate of 108,489,511 of our Ordinary Shares represented by 21,697,902 Depositary Shares, consisting of (i) 3,250,200 Ordinary Shares represented by 650,040 Depositary Shares, (ii) 12,931,027 Ordinary Shares represented by 2,586,205 Depositary Shares, issuable upon the exercise of Series A warrants issued in the February Private Placement, (iii) 19,396,545 Ordinary Shares represented by 3,879,309 Depositary Shares, issuable upon the exercise of Series B warrants issued in the February Private Placement, and (iv) up to 71,749,800 Ordinary Shares represented by 14,349,960 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the February Private Placement, subject to certain reset provisions set forth in the pre-funded warrants, at an initial purchase price of $2.32 per Depositary Share, for aggregate gross proceeds of approximately $6.0 million.

In addition, in connection with the February Private Placement, on February 9, 2023 we entered into a Waiver to the Securities Purchase Agreement, dated as of December 13, 2022, or the Waiver, by and between the Company and a certain institutional investor, or the December Investor, as amended on December 16, 2022, or the December SPA, providing for a permanent waiver of certain equity issuance prohibitions and participation rights under the December SPA. In connection therewith, we agreed to, subject to receipt of stockholder approval, issue to the December Investor Series A warrants exercisable for 625,000 Ordinary Shares represented by 125,000 Depositary Shares. Further, we issued to the placement agent in the February Private Placement, Ladenburg Thalmann & Co. Inc., or Ladenburg, placement agent warrants to purchase 536,938 Ordinary Shares represented by 107,387 Depositary Shares, or the Ladenburg Warrants.

On March 24, 2023, we held a general meeting where our shareholders approved, among other things, the allotment of, and disapplication of preemption rights with respect to, the Ordinary Shares to be issued under the Series A warrants, the Series B warrants, certain of the pre-funded warrants, and the Ladenburg Warrants. We subsequently issued the warrants to the investors and Ladenburg.

Reverse Stock Split, Change of Name and AIM Cancellation

On March 24, 2023, we held a general meeting where our shareholders approved, among other things, (i) a change of our name to “Biodexa Pharmaceuticals PLC,” (ii) the allotment of up to 100% of our fully diluted share capital for future share issuances through our annual general meeting in 2025, (iii) the cancellation of admission of our Ordinary Shares from trading on AIM, and (iv) a one-for-20 reverse stock split of our Ordinary Shares. The reverse stock split of our Ordinary Shares was effective as of March 27, 2023.

Concurrently with the reverse split, and in order to continue meeting The NASDAQ Stock Market LLC’s, or NASDAQ, minimum 500,000 publicly held shares requirement pursuant to Rule 5550(a)(4), on March 27, 2023, we changed the ratio of Depositary Shares from one Depositary Share representing 25 Ordinary Shares to a new ratio of one Depositary Share representing five Ordinary Shares. This had the effect of a one-for-four reverse split of our Depositary Shares. There can be no assurance that the ratio change will be effective in achieving our goal of regaining compliance with NASDAQ’s minimum bid price requirement.

The change in the number of Ordinary Shares and Depositary Shares resulting from the reverse stock split and change in ratio, respectively, has been applied retroactively to all share and per share amounts presented in this prospectus.

Additionally, as noted above, our shareholders have approved the cancellation of admission of our Ordinary Shares on AIM. This cancellation became effective on April 26, 2023. The Depositary Shares trade exclusively on NASDAQ under the symbol “BDRX.” There is currently no market for our Ordinary Shares.

Terminated Transaction with Bioasis Technologies Inc.

On December 13, 2022, we entered into an arrangement agreement, or Arrangement Agreement, with Bioasis Technologies Inc., or Bioasis, pursuant to which (i) we were to acquire all of the issued and outstanding common shares of Bioasis, or the Bioasis Shares, in exchange for our Ordinary Shares (to be issued in the form of Depositary Shares), and (ii) Bioasis would become our wholly owned subsidiary. The closing of the transaction was subject to a number of closing conditions, including the receipt of our shareholders’ approval.

S-7

Table of Contents

In addition, in connection with entering into the Arrangement Agreement, Bioasis issued to us a promissory note, or the Note, in consideration for a loan from us, which loan was to be made in three tranches of $250,000 payable on each of December 19, 2022, January 3, 2023 and February 6, 2023, in each case, subject to written demand and to the terms and conditions of the Note. As of the date hereof, we have loaned Bioasis $500,000 under the Note.

On January 23, 2023, following the failure by our shareholders to approve the necessary resolutions to complete the transaction, Bioasis terminated the Arrangement Agreement and the transactions related thereto.

In connection with the termination of, and pursuant to the terms of, the Arrangement Agreement, Bioasis has demanded an expense reimbursement of $225,000. In addition, on February 27, 2023, Bioasis demanded the third payment of $250,000 under the Note. We have notified Bioasis that it is in default under the terms of the Note and have demanded repayment immediately of all amounts owed to us under the Note.

Registered Direct Offering and Termination of Proposed Private Placement

On December 16, 2022, we completed the closing of a registered direct offering, or the December Registered Direct, with the December Investor, for the sale of 492,466 Ordinary Shares represented by 98,493 Depositary Shares at a price per Depositary Share of $4.00, for aggregate gross proceeds of approximately $0.4 million.

On January 26, 2023, following the termination of the Arrangement Agreement by Bioasis, we terminated the December SPA, and the Registration Rights Agreement, by and between the Company and the December Investor, dated as of December 13, 2022, pursuant to which we would have sold such December Investor $9.6 million of our securities, subject to the closing of the transactions contemplated by the Arrangement Agreement.

MTX110 Developments

On June 1, 2022, we announced that upon submitting an application to the U.S. Food and Drug Administration, or the FDA, our development program of MTX110 for the treatment of recurrent glioblastoma had been granted Fast Track designation by the agency. Fast Track is a process designed to facilitate the development and expedite the review of treatments for serious conditions and that potentially address unmet medical needs. Drugs that are granted this designation are given the opportunity for more frequent interactions with the FDA, as well as potential pathways for expedited approval.

On January 12, 2023, we announced that, following completion of one-month treatment with MTX110 in our first patient, our Phase I study of MTX110 in recurrent glioblastoma would continue with a planned dose escalation following positive recommendation from the study’s Data Safety Monitoring Board, or DSMB. The Phase I study is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery via implanted refillable pump and catheter. The study aims to recruit two cohorts, each with a minimum of four patients; the first cohort will receive MTX110 only and the second cohort will receive MTX110 in combination with lomustine.

The first patient in the study was dosed at 60uM of MTX110 via direct-to-tumour delivery and has received four 48-hour infusions over a period of four weeks. No treatment-associated adverse events were noted in the patient during this period. Following successful completion of the first month of treatment, the DSMB reviewed the available data and recommended dose escalation in the study to 90uM. This dose is expected to be the optimal one of MTX110 and is the one currently being used in the ongoing Phase I study of patients with DIPG at Columbia University.

Non-Compliance with NASDAQ Continued Listing Requirements

Our Depositary Shares are currently listed on the NASDAQ Capital Market. We are required to meet certain qualitative and financial tests to maintain the listing of our Depositary Shares on NASDAQ. On January 31, 2023, we received a letter from NASDAQ stating that, for the previous 30 consecutive business days, the bid price for our Depositary Shares had closed below the minimum $1.00 bid price per share requirement for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of our Depositary Shares and the Depositary Shares will continue to trade on the NASDAQ Capital Market under the symbol “BDRX.”

S-8

Table of Contents

In accordance with NASDAQ Listing Rules, we have a grace period of 180 calendar days, or until July 31, 2023, or the Compliance Period, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Depositary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the Compliance Period. If the Depositary Shares do not regain compliance with the minimum bid price requirement during the Compliance Period, we may be eligible for an additional grace period of 180 calendar days provided that we satisfy NASDAQ's initial listing standards for listing on the NASDAQ Capital Market, other than the minimum bid price requirement, and provide written notice to NASDAQ of its intention to cure the delinquency during the second grace period. If we do not regain compliance during the initial grace period and are not eligible for an additional grace period, NASDAQ will provide written notice that the Depositary Shares are subject to delisting from the NASDAQ Capital Market. In that event, we may appeal such determination to a hearing panel.

We intend to monitor the bid price of our Depositary Shares during the Compliance Period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods.

Our Pipeline and Platform Technologies

We are actively pursuing the development of MTX110 in three Phase I studies. Our other product candidates, MTD201, Q-octreotide and MTD211, Q-brexpiprazole are not being actively developed but are available for licensing. MTX223 is a research and development collaboration with Janssen. Our development pipeline includes six projects as follows:

Corporate Information

Our principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our principal executive office is +44 29 2048 0180. Our service agent in the United States is located at Puglisi and Associates, 850 Library Avenue Newark, Delaware 19711. Our Depositary Shares, each representing five Ordinary Shares, are listed on the NASDAQ under the symbol “BDRX.” Our website is located at http://biodexapharma.com. We do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus.

Additional Information

For additional information related to our business and operations, please refer to the reports incorporated herein by reference, including our 2022 Annual Report, as filed with the SEC on April 28, 2023, as amended on May 5, 2023, and our Reports on Form 6-K as filed with the SEC, as described in the section titled “Incorporation of Certain Information by Reference.”

S-9

Table of Contents

The Offering

Registered Depositary Shares offered by us		22,135,922 Registered Depositary Shares, each representing 5 ordinary shares

Price per Registered Depositary Share		$0.15

Ordinary Shares Outstanding at May 19, 2023		96,679,412

Depositary Shares to be outstanding immediately after the offering		41,471,804 Depositary Shares equivalent

Ordinary shares to be outstanding immediately after the offering		207,359,022 ordinary shares (including those represented by Registered Depositary Shares)

Private placement		In the Private Placement, we will also issue to the purchasers in this offering (i) Depositary Share purchase warrants exercisable for an aggregate of 33,203,883 Depositary Shares, or the Series C Warrants and (ii) Depositary Share purchase warrants exercisable for an aggregate of 22,135,922 Depositary Shares, or the Series D Warrants, and collectively with the Series C Warrants, the Warrants. The Warrants will be exercisable at an exercise price of $0.20 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The Warrants will become exercisable upon receipt of Shareholder Approval to allot the Warrants, the Depositary Shares issuable upon the exercise of the Warrants, or the Warrant ADSs, and the ordinary shares underlying the Warrant ADSs, or the Warrant Shares offered in the Private Placement without triggering statutory preemptive rights under the laws of England and Wales. The Series C Warrants will expire one year from the initial exercise date and may be exercised on a cashless basis, subject to the satisfaction of payment of not less than the nominal value of the ordinary share under the provisions of the Companies Act. The Series D Warrants will expire five years from the initial exercise date Six months after the issuance date of the Series D Warrants, if and only if there is no effective registration statement registering the applicable Depositary Shares, or no current prospectus available for such shares, the resale of the Depositary Shares issuable upon exercise of the Series D Warrants, the purchaser may exercise the Series D Warrants by means of a "cashless exercise," subject to the satisfaction of payment of not less than the nominal value of the ordinary share under the provisions of the Companies Act. A holder of the Warrants may not exercise the Warrants if the holder, together with its affiliates, would beneficially own more than 4.99% or 9.99% (such amount to be determined at the option of the holder) of the number of ordinary shares outstanding immediately after giving effect to such exercise. The Warrants, the Warrant ADSs, and the Warrant Shares are not being registered under the Securities Act, pursuant to the registration statement of which this prospectus supplement and the accompanying base prospectus form a part, nor are such Warrants, Warrant ADSs and Warrant Shares being offered pursuant to such prospectus supplement and base prospectus. The Warrants are being offered pursuant to the exemption provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The Warrants are not, and will not be, listed for trading on any national securities exchange. Each investor will be an “accredited investor” (as such term is defined in Rule 501(a) under the Securities Act) or “qualified institutional buyer” (as such term is defined in Rule 144A under the Securities Act).

Leak-Out Agreements		Certain investors in the offering entered into leak-out agreements pursuant to which each such investor agreed to certain limits on sales of the Ordinary Shares and/or ADSs, including ADSs purchased in this offering and the ADSs issuable upon the exercise of the Warrants. See “Plan of Distribution” for additional information.

Depositary Shares		Each Registered Depositary Share represents 5 ordinary shares. The depositary (through its custodian) will hold the ordinary shares underlying your Registered Depositary Shares. You will have rights as provided in the amended and restated deposit agreement among us, The Bank of New York Mellon, as depositary, and all owners and holders from time to time of Depositary Shares issued thereunder, or the deposit agreement. You may, among other things, cancel your Registered Depositary Shares and withdraw the underlying ordinary shares against a fee paid to the depositary (which may be reimbursable by the Company). In certain limited instances described in the deposit agreement, we may amend or terminate the deposit agreement without your consent. If you continue to hold your Registered Depositary Shares, you agree to be bound by the terms of the deposit agreement then in effect.

S-10

Table of Contents

		To better understand the terms of the Registered Depositary Shares and the deposit agreement, including applicable fees and charges, you should carefully read “Description of American Depositary Shares” in this prospectus supplement. You should also read the deposit agreement, which is an exhibit to the registration statement that includes this prospectus supplement.

Depositary		The Bank of New York Mellon

Use of proceeds		We currently intend to use the net proceeds from the sale of our securities, together with existing cash and cash equivalents for working capital and for general corporate purposes. See “Use of Proceeds” for additional information.

Risk factors		Investing in our securities involves a high degree of risk. You should read the “Risk Factors” section starting on page [S-12] of this prospectus supplement and page 4 of the accompanying prospectus, as well as those risk factors that are incorporated by reference in this prospectus supplement, for a discussion of factors to consider before deciding to invest in our securities.

Trading symbol on the NASDAQ Capital Market for Depositary Shares		“BDRX”

The number of our ordinary shares outstanding after this offering is based on 96,679,412 ordinary shares outstanding as of May 19, 2023, and excludes:

•

121,340 ordinary shares issuable upon the exercise of stock options outstanding under our equity incentive plans at a weighted-average exercise price of £5.05 per share;

•

138 ordinary shares issuable upon the exercise of stock options assumed in connection with the acquisition of DARA Biosciences, Inc., or DARA, at a weighted-average exercise price of $1,903.40 per share;

•

warrants, issued to an investor in an October 2019 private placement, exercisable for 30,000 Depositary Shares (representing 150,000 ordinary shares), at an exercise price of $4.00 per Depositary Share;

•

warrants, issued to the placement agent in connection with an October 2019 private placement, exercisable for 1,499 Depositary Shares (representing 7,495 ordinary shares), at an exercise price of $125.00 per Depositary Share;

•

warrants, issued to an investor in a May 2020 private placement, exercisable for 32,550 Depositary Shares (representing 162,750 ordinary shares), at an exercise price of $4.00 per Depositary Share;

•

warrants, issued to various investors in a May 2020 private placement, exercisable for 33,357 Depositary Shares (representing 166,785 ordinary shares), at an exercise price of $41.00 per Depositary Share;

•

warrants, issued to the placement agent in connection with the May 2020 private placement, exercisable for 1,476 Depositary Shares (representing 7,380 ordinary shares), at an exercise price of $41.25 per Depositary Share;

•

warrants, issued in a May 2020 placing in the United Kingdom, exercisable for 349,999 ordinary shares, at an exercise price of £6.80 per share;

•

warrants, issued in February 2023 to the placement agent in connection with the December 2022 registered direct offering, exercisable for 3,939 Depositary Shares (representing 19,695 ordinary shares) at an exercise price of $5.00 per Depositary Share;

•

warrants, issued in February 2023 to the placement agent in connection with the December 2022 private placement, exercisable for 103,448 Depositary Shares (representing 517,240 ordinary shares) at an exercise price of $2.90 per Depositary Share;

•

warrants, issued in February 2023 to an investor in connection with the December 2022 private placement, exercisable for 125,000 Depositary Shares (representing 625,000 ordinary shares) at an exercise price of $2.68 per Depositary Share;

•

warrants, issued in August 2022, exercisable for 16,666 ordinary shares, at an exercise price of £2.70 per share; and

•

Ordinary Shares issuable upon exercise of the Warrants to be issued in this private placement and to be issued to the placement agent.

Except as otherwise indicated, all information in this prospectus supplement assumes that the Warrants offered hereby are not exercised.

S-11

Table of Contents

RISK FACTORS

An investment in our securities involves risks. We urge you to consider carefully the risks described below, and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision, including those risks identified under “Item 1A. Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2022, which is incorporated by reference in this prospectus supplement and which may be amended, supplemented or superseded from time to time by other reports that we subsequently file with the SEC. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled “Cautionary Note Regarding Forward-Looking Statements.”

Risks Related to the Offering

Future sales of our Depositary Shares (or the underlying ordinary shares), or the perception that such sales may occur, could cause the market price of our Depositary Shares (and the underlying ordinary shares) to fall.

Sales of a substantial number of our Depositary Shares (or the underlying ordinary shares) in the public market, or the perception that these sales could occur, following this offering could cause the market price of our Depositary Shares (and the underlying ordinary shares) to decline. A substantial majority of the outstanding securities are, and the Depositary Shares sold in this offering upon issuance will be, freely tradable without restriction or further registration under the Securities Act.

Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.

Our management will have broad discretion as to the use of the net proceeds from any offering by us and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for us.

We will require additional capital funding, the receipt of which may impair the value of our Depositary Shares.

Our future capital requirements depend on many factors, including our research, development, sales and marketing activities. We will need to raise additional capital through public or private equity or debt offerings or through arrangements with strategic partners or other sources in order to continue to develop our product candidates. There can be no assurance that additional capital will be available when needed or on terms satisfactory to us, if at all. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution and the new equity securities may have greater rights, preferences or privileges than our existing Depositary Shares.

S-12

Table of Contents

We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our Depositary Shares.

We have never paid cash dividends on our ordinary shares (and, by extension our Depositary Shares) and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our capital stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our Depositary Shares may be less valuable because a return on your investment will only occur if the Depositary Share price appreciates.

There can be no assurance that the transaction between the Company and Varian will be consummated or that any definitive agreement will be executed by the parties with respect to any proposed transaction.

Failure to execute any such definitive agreement and/or complete the transaction could have an adverse effect on the Company’s stock price, business, financial condition, results of operations or prospects. The Company and Varian will incur significant transaction costs in connection with the transaction. The Company may fail to realize some or all of the anticipated benefits of the proposed transaction with Varian, which may adversely affect the value of the Company’s securities.

If we cannot meet NASDAQ’s continued listing requirements, NASDAQ may delist our Depositary Shares, which could have an adverse impact on the liquidity and market price of our Depositary Shares.

Our Depositary Shares are currently listed on the NASDAQ Capital Market. We are required to meet certain qualitative and financial tests to maintain the listing of our Depositary Shares on NASDAQ. On January 31, 2023, we received a letter from NASDAQ stating that, for the previous 30 consecutive business days, the bid price for our Depositary Shares had closed below the minimum $1.00 bid price per share requirement for continued listing on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2).

We cannot assure you that we will regain compliance, or if we do regain compliance, that we will remain in compliance with all applicable requirements for continued listing on the NASDAQ Capital Market. If we fail to sustain compliance with all applicable requirements for continued listing on NASDAQ, our Depositary Shares may be subject to delisting by NASDAQ. This could inhibit the ability of our holders of Depositary Shares to trade their shares in the open market, thereby severely limiting the liquidity of such shares. Although stockholders may be able to trade their shares of Depositary Shares on the over-the-counter market, there can be no assurance that this would occur. Further, the over-the-counter market provides significantly less liquidity than NASDAQ and other national securities exchanges, is thinly traded and highly volatile, has fewer market makers and is not followed by analysts. As a result, your ability to trade or obtain quotations for these securities may be more limited than if they were quoted on NASDAQ or other national securities exchanges.

S-13

Table of Contents

CAPITALIZATION

The following table sets forth our capitalization as of December 31, 2022:

on an actual basis; and

on a pro-forma as adjusted basis, to give effect to the issuance and sale by us of

(i)

the February 2023 Private Placement and the issuance of the Ladenburg Warrants in the February Private placement, after deducting the placement agent fees and estimated offering expenses by us; and

(ii)

22,135,922 Depositary Shares, representing 110,679,610 ordinary shares, in this offering at an offering price of $0.15 per Depositary Share, after deducting the placement agent fees and estimated offering expenses payable by us in this offering.

You should read this table in conjunction with the section of this prospectus supplement under the caption “Use of Proceeds”, as well as our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and other financial information included or incorporated by reference in this prospectus supplement.

	As of December 31, 2022
	Actual			Pro Forma As Adjusted(1)(2)
	(£’s in thousands, except share and per share data)
Cash and cash equivalents		2,836			8,973
Long-term debt		(463	)		(463	)
Total equity		3,162			4,886
Total capitalization		3,625			5,349

________

(1) The proceeds from the February Private Placement have been translated into British pounds sterling at a rate of £1.00 to $1.2078.

(2) The fair value of the warrants issued in the February Private Placement has been calculated, as of February 15, 2023, and recorded as a current liability of £4,615,220 and debit to share premium of £4,615,220.

The table above does not include:

•

121,340 ordinary shares issuable upon the exercise of stock options outstanding under our equity incentive plans at a weighted-average exercise price of £5.05 per share;

•

warrants, issued to an investor in a May 2020 private placement, exercisable for 32,550 Depositary Shares (representing 162,750 ordinary shares), at an exercise price of $4.00 per Depositary Share;

•

warrants, issued in a May 2020 placing in the United Kingdom, exercisable for 349,999 ordinary shares, at an exercise price of £6.80 per share;

•

warrants, issued in February 2023 to the placement agent in connection with the December 2022 private placement, exercisable for 125,000 Depositary Shares (representing 625,000 ordinary shares) at an exercise price of $2.68 per Depositary Share;

•

warrants, issued in August 2022, exercisable for 16,666 ordinary shares, at an exercise price of £13.50 per share; and

•

Ordinary Shares issuable upon exercise of the Warrants to be issued in this private placement and to be issued to the placement agent.

S-14

Table of Contents

USE OF PROCEEDS

We expect that our net proceeds from the offering will be approximately $2.61 million, after deducting the placement agent fees and estimated offering expenses payable by us and excluding any proceeds we may receive upon the cash exercise of the Warrants being offered in the private placement. However, each Warrant may be exercised on a cashless basis, subject to the satisfaction of payment of not less than the nominal value of the ordinary share under the provisions of the Companies Act, and therefore it is likely we will not receive any proceeds from the exercise of such Warrants. We can make no assurances that any of the Warrants will be exercised, or if exercised, the quantity which will be exercised or in the period in which they will be exercised, or that they will be exercised for cash.

We anticipate that we will use the net proceeds of the offering, and to the extent the Warrants are exercised for cash, for working capital and for general corporate purposes.

Although it is difficult to predict future liquidity requirements, we believe that the net proceeds from the offering, including the Private Placement, and our existing cash and cash equivalents, together with interest thereon, will be sufficient to fund our operations for into the first quarter of 2024.

The expected use of the net proceeds from the offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures depend on numerous factors, including the signing of a definitive agreement with Varian Biopharmaceuticals, Inc., and the closing of the transactions set forth therein, the ongoing status of and results from our clinical trials and other studies, the progress of our preclinical development efforts and any unforeseen cash needs. As a result, our management will have broad discretion in applying the net proceeds of the offerings.

Pending their use, we plan to invest the net proceeds of this offering in short-term, interest-bearing investments.

S-15

Table of Contents

dividend policy

Since inception, we have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends on our Ordinary Shares or the Depositary Shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. As a result, investors in the Ordinary Shares and Depositary Shares will benefit in the foreseeable future only if the Ordinary Shares and Depositary Shares appreciate in value.

Any determination to pay dividends in the future would be at the discretion of our Board of Directors and will depend upon our results of operations, cash requirements, financial condition, contractual restrictions, and any future debt agreements and is subject to compliance with applicable laws, including the Companies Act, which requires English companies to have profits available for distribution equal to or greater than the amount of the proposed dividend.

S-16

Table of Contents

DILUTION

Our net tangible book value as of December 31, 2022 was approximately $3.9 million, or $3.60 per Depositary Share. Net tangible book value per Depositary Share is determined by dividing our total tangible assets, less total liabilities, by the number of our ordinary shares outstanding as of December 31, 2022, and multiplying such amount by 5 (one Depositary Share represents 5 ordinary shares). Pro forma net tangible book value at December 31, 2022 was $9.0 million, or $0.44 per Depositary Share, after giving effect to the sale of 650,040 Depositary Shares, issue of 12,436,905 pre-funded Depositary share warrants, issue of 2,586,204 A Depositary Share warrants and 3,879,306 B Depositary Share warrants subsequent to February 15, 2023 in connection with a private placement, after deducting the estimated placement agent’s fees and estimated offering expenses payable by us. Dilution in net tangible book value per Depositary Share represents the difference between the amount per Registered Depositary Share paid by the purchaser of Registered Depositary Shares in this offering and the net tangible book value per share of our Depositary Shares immediately after this offering.

After giving effect to the sale of 22,135,922 Registered Depositary Shares in this offering at an offering price of $0.15 per Registered Depositary Share, after deducting the placement agent fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2022 would have been approximately $11.6 million, or $0.27 per Depositary Share. This represents an immediate decrease in net tangible book value of $0.17 per Depositary Share to existing shareholders and immediate accretion in net tangible book value of $0.12 per Registered Depositary Share to the investor purchasing our Registered Depositary Shares in this offering.

The following table illustrates this dilution on a per Depositary Share basis:

	As at December 31, 2022
	Per American Depositary Shares
Offering price per Registered Depositary Share	$	0.15
Historical net tangible book value per Depositary Share as of December 31, 2022		3.60
Adjustment for shares issued on February 15, 2023		(3.16)
Pro forma net tangible book value per Depositary Share as of December 31, 2002		0.44
Decrease in pro-forma as adjusted net tangible book value per Depositary Share attributable to the investor in this offering		(0.17)
Pro forma as adjusted net tangible book value per Depositary Share immediately after this offering		0.27
Accretion per Registered Depositary Share to the investor in this offering		0.12

________

(1) The change in the number of Ordinary Shares resulting from the reverse stock split and change in the number of Depostiary Shares resultinfr om the change in ratio has been applied retroactively to all share and per share amounts presented in this prospectus supplement.

The above discussion and tables are based on 5,417,137 ordinary shares outstanding as of December 31, 2022 and excludes:

•

121,340 ordinary shares issuable upon the exercise of stock options outstanding under our equity incentive plans at a weighted-average exercise price of £5.05 per share;

•

warrants, issued to an investor in a May 2020 private placement, exercisable for 32,550 Depositary Shares (representing 162,750 ordinary shares), at an exercise price of $4.00 per Depositary Share;

•

warrants, issued in a May 2020 placing in the United Kingdom, exercisable for 349,999 ordinary shares, at an exercise price of £6.80 per share;

•

warrants, issued in August 2022, exercisable for 16,666 ordinary shares, at an exercise price of £2.70 per share; and

•

Ordinary Shares issuable upon exercise of the Warrants to be issued in this private placement and to be issued to the placement agent.

To the extent that outstanding options or other securities are exercised or converted into ordinary shares or Depositary Shares, the investor purchasing our Registered Depositary Shares in this offering will experience significant further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders.

S-17

Table of Contents

PRIVATE PLACEMENT TRANSACTION AND WARRANTS

In the Private Placement, we will also issue to the purchaser in this offering (i) Depositary Shares purchase warrants exercisable for an aggregate of 33,203,883 Depositary Shares, or the Series C Warrants and (ii) Depositary Shares purchase warrants exercisable for an aggregate of 22,135,922 Depositary Shares, or the Series D Warrants, and collectively with the Series C Warrants, the Warrants. The Warrants will be exercisable at an exercise price of $0.20 per Depositary Shares, subject to adjustments for certain dilutive equity issuances. The Warrants will become exercisable upon receipt of Shareholder Approval to allot the Warrants, the Depositary Shares issuable upon the exercise of the Warrants, or the Warrant ADSs, and the ordinary shares underlying the Warrant ADSs, or the Warrant Shares offered in the Private Placement without triggering statutory preemptive rights under the laws of England and Wales. The Series C Warrants will expire one year from the initial exercise date and may be exercised on a cashless basis, subject to the satisfaction of payment of not less than the nominal value of the ordinary shares under the provisions of the Companies Act. The Series D Warrants will expire five years from the initial exercise date. A holder of the Warrants may not exercise the Warrants if the holder, together with its affiliates, would beneficially own more than 4.99% or 9.99% (such amount to be determined at the option of the holder) of the number of ordinary shares outstanding immediately after giving effect to such exercise.

The exercise price and number of shares of Depositary Shares issuable upon the exercise of the Warrants will be subject to adjustment in the event of any stock dividend and split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants.

The Warrants, the Warrant ADSs and the Warrant Shares are not being registered under the Securities Act pursuant to the registration statement of which this prospectus supplement and the accompanying base prospectus form a part and are not being offered pursuant to this prospectus supplement and the accompanying base prospectus. The Warrants, Warrant ADSs and Warrant Shares are being offered pursuant to the exemption provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder.

In connection with the offering, we entered into a registration rights agreement with the investors, dated May 23, 2023, or the Registration Rights Agreement. The Registration Rights Agreement provides that we shall file a registration statement, or Resale Registration Statement, covering the resale of all of the Warrants, Warrant ADSs and Warrant Shares with the SEC no later than the 30th calendar day following the date of the closing of the Private Placement, and have the registration statement declared effective by the SEC as promptly as possible after the filing thereof, but in any event no later than the 90th calendar day following the closing of the Private Placement or on the event that the SEC notifies us that the registration statement will not be reviewed or is no longer subject to further review and comments, the fifth trading day following the date that we receive such notification.

On or after the date of exercise, a holder of the Series C Warrants may also provide notice and elect an “alternative cashless exercise” pursuant to which they would receive an aggregate number of Depositary Shares equal to the product of (x) the aggregate number of Depositary Shares that would be issuable upon a cash exercise and (y) 1.0. Six months after the issuance date of the Series D Warrants, if and only if there is no effective registration statement registering the applicable Depositary Shares, or no current prospectus available for such shares, the resale of the Depositary Shares issuable upon exercise of the Warrants, the purchaser may exercise the Warrants by means of a “cashless exercise, subject to the satisfaction of payment of not less than the nominal value of the ordinary shares under the provisions of the Companies Act.”

The investor is required to be an “accredited investor” (as such term is defined in Rule 501(a) under the Securities Act) or a “qualified institutional buyer” (as such term is defined in Rule 144A under the Securities Act).

There is no established public trading market for the Warrants, and we do not expect a market to develop. We do not intend to list the Warrants on the NASDAQ Capital Market, any other national securities exchange or any other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will be limited.

S-18

Table of Contents

DESCRIPTION OF OUR SHARE CAPITAL

The following describes our issued share capital, summarizes the material provisions of our Articles of Association and highlights certain differences in corporate law in the United Kingdom and the United States. This description of our share capital and summary of our Articles of Association is not complete, and is qualified by reference to our Articles of Association. You should read our Articles of Association, which are incorporated by reference into this prospectus supplement for the provisions that are important to you.

General

We are a public limited company organized under the laws of England and Wales under registered number 09216368. Our registered office is 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The principal legislation under which we operate and our shares are issued is the Companies Act.

Issued Share Capital

Our issued share capital as of December 31, 2022 and May 19, 2023 was 5,417,137 Ordinary Shares and 96,679,412 Ordinary Shares, respectively. Each Ordinary Share has a nominal value £0.02 per share. Each issued Ordinary Share is fully paid. We currently have 1,000,001 deferred shares and no preference shares in our issued share capital.

There is no limit to the number of Ordinary Shares or preference shares that we are authorized to issue, as the concept of authorized capital is no longer applicable under the provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to any ordinary shares.

We are not permitted under English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any of our own ordinary shares.

History of Share Capital

On May 20, 2020, we issued 454,545 Ordinary Shares represented by 90,909 Depositary Shares in a registered direct offering with certain institutional investors for aggregate gross proceeds of $3.0 million. In addition, in a concurrent private placement, we issued warrants to purchase a total of 454,545 Ordinary Shares represented by 90.909 Depositary Shares at an exercise price of $10.25 per Depositary Share, and warrants to purchase a total of 22,727 Ordinary Shares represented by 4,545 Depositary Shares to affiliates of Wainwright in the private placement at an exercise price of $10.3125 per Depositary Share.

On May 22, 2020, we issued 333,333 Units to certain investors in a placing in the United Kingdom for aggregate gross proceeds of £1.8 million. Each Unit comprised one new Ordinary Share and one warrant to purchase Ordinary Share, or a UK Warrant, with an exercise price of £1.70 per share. We also issued UK Warrants to purchase a total of 16,666 Ordinary Shares to Turner Pope, the placing agent, in connection with the closing of such offering, on the same terms and conditions as the other investors in the offering.

On July 27, 2020, we issued 1,064,814 Ordinary Shares, including 138,888 Ordinary Shares issued pursuant to a broker option, to certain non-U.S. investors in a placing in the United Kingdom for aggregate gross proceeds of £5.75 million.

On August 19, 2020, we issued 125,000 Ordinary Shares represented by 25,000 Depositary Shares upon the exercise of warrants issued in May 2020 at an exercise price of $51.25 per share.

On September 30, 2020, we issued 1,250 Ordinary Shares to be purchased under the Midatech Pharma Share Incentive Plan.

S-19

Table of Contents

On February 19, 2021, we issued 15,340 Ordinary Shares represented by 613 Depositary Shares upon the exercise of warrants issued in May 2020 at an exercise price of $51.5625 per share.

On July 6, 2021, we issued 1,754,386 Ordinary Shares to certain non-U.S. investors in a placing in the United Kingdom for aggregate gross proceeds of £10.0 million.

On March 22, 2022, we issued one Ordinary Share upon the exercise of one warrant issued in February 2019 at an exercise price of £50 per share.

On May 3, 2022, we issued 1,250 Ordinary Shares to be purchased under the Midatech Pharma Share Incentive Plan.

On August 3, 2022, we issued warrants to purchase 16,666 Ordinary Shares at an exercise price of £2.70 per share.

On September 26, 2022, we effected a ratio change to our Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such that one Depositary Share represented 25 Ordinary Shares. Our Ordinary Shares were not affected by this change.

On December 16, 2022, we sold to an institutional investor 492,466 Ordinary Shares represented by 98,493 Depositary Shares in a registered direct offering at $5.00 per Depositary Share, resulting in gross proceeds of approximately $0.4 million.

On February 15, 2023, we completed the closing of the February Private Placement pursuant to which we sold to certain institutional investors (1) 3,250,200 Ordinary Shares represented by 650,040 Depositary Shares, (2) 12,931,027 Ordinary Shares represented by 2,586,205 Depositary Shares, issuable upon the exercise of Series A warrants issued in the February Private Placement, (3) 19,396,545 Ordinary Shares represented by 3,879,309 Depositary Shares, issuable upon the exercise of Series B warrants issued in the February Private Placement, and (4) up to 71,749,800 Ordinary Shares represented by 14,349,960 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the February Private Placement, for aggregate gross proceeds of approximately $6.0 million.

In addition, in connection with the February Private Placement, we issued 536,938 Ordinary Shares represented by 107,387 Depositary Shares upon the exercise of placement agent warrants, and a Series A warrant exercisable for 625,000 Ordinary Shares presented by 125,000 Depositary Shares to the December Investor in connection with the Waiver.

On March 27, 2023, following shareholder approval, we effected a one-for-20 reverse split of our Ordinary Shares, and our Ordinary Shares began trading on AIM on a split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock split. As a result of the reverse stock split, the number of issued and outstanding Ordinary Shares was reduced to 8,667,337 shares as of March 27, 2023.

Concurrently with the reverse split, and in an effort to bring our Depositary Shares price into compliance with NASDAQ’s minimum bid price per share requirement, on March 27, 2023 we effected a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 25 Ordinary Shares per Depositary Share to five Ordinary Shares per Depositary Share.

Between March 27, 2023 and the date hereof, we have issued 88,012,075 Ordinary Shares upon the exercise of 17,602,415 pre-funded warrants, Series A warrants and Series B warrants issued in the February Private Placement.

Options

We have established the 2014 Enterprise Management Incentive Scheme, or the EMI Scheme, pursuant to which we have issued options to purchase Ordinary Shares to employees and directors. As of May 19, 2023, there were options to purchase 103,815 Ordinary Shares under the EMI Scheme. In addition, as of May 19, 2023, there were options to purchase 17,525 Ordinary Shares under non-approved schemes. The options lapse after ten years from the date of the grant.

S-20

Table of Contents

As of March 31, 2023, the weighted average remaining life of the option under the EMI Scheme and non-approved options schemes was 8.1 years.

In connection with our acquisition of DARA in December 2015, we assumed all of DARA’s outstanding options, or DARA Options. As of May 19, 2023, there were outstanding DARA Options to purchase 138 Ordinary Shares.

Warrants

October 2019 and May 2020 Warrants

The following is a brief summary of the October Private Placement Warrants, Wainwright October Warrants, May Private Placement Warrants and Wainwright May Warrants issued in connection with the October Private Placement and May Private Placement, as applicable, and is subject in all respects to the provisions contained in the applicable warrants, which, with respect to the October Private Placement Warrants and Wainwright October Warrants, are filed as exhibits to our Report on Form 6-K dated October 24, 2019, and for the May Private Placement Warrants and Wainwright May Warrants, are filed as exhibits to our Report on Form 6-K dated May 20, 2020. Unless otherwise stated, references to warrants in this section include the October Private Placement Warrants, May Private Placement Warrants, Wainwright October Warrants and Wainwright May Warrants.

Exercisability. The October Private Placement Warrants and Wainwright October Warrants became exercisable on December 23, 2019. The May Private Placement Warrants and Wainwright May Warrants became exercisable upon issuance. The October Private Placement Warrants and May Private Placement Warrants will expire five and one-half years from the initial exercise date, and the Wainwright October Warrants and Wainwright May Warrants will expire on October 22, 2024 and May 18, 2025, respectively. The holder shall deliver the aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise (subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise. With respect to the October Private Placement Warrants and Wainwright October Warrants, if, more than six months after the date of issuance of such warrants, there is no effective registration statement registering, or no current prospectus available for, the resale of the Depositary Shares underlying such warrants, the holder may exercise the warrant, in whole or in part, on a cashless basis. With respect to the May Private Placement Warrants and Wainwright May Warrants, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Depositary Shares underlying such warrants, the holder may exercise the warrant, in whole or in part, on a cashless basis.

Exercise Price. The exercise price of (i) each October Private Placement Warrant and Wainwright October Warrant is $6.25 per Depositary Share and (ii) each May Private Placement Warrants and Wainwright May Warrant is $2.05 and $2.0625 per Depositary Share, respectively, each subject to the ‘cashless exercise’ arrangements described above and to adjustment as described below.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder or any such affiliate, would beneficially own in excess of, at the initial option of the holder thereof, 4.99% or 9.99%, as applicable, of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Depositary Shares upon such exercise. The holder of the warrant, upon notice to us, may increase or decrease the beneficial ownership limitation to a percentage not to exceed 9.99%, provided that any increase in the beneficial ownership limitation shall not be effective until 61 days following notice to us. Beneficial ownership of the holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange Act, and the rules and regulations promulgated thereunder.

Stock dividends and stock splits. If we pay a stock dividend or otherwise make a distribution payable in Depositary Shares or Ordinary Shares, or any other equity or equivalent securities, subdivide or combine outstanding Depositary Shares or Ordinary Shares, or reclassify Depositary Shares, Ordinary Shares or any shares of our capital stock, the exercise price of each warrant will be adjusted by multiplying the then exercise price by a fraction, the numerator of which shall be the number of Depositary Shares (excluding treasury shares, if any) outstanding immediately before such event, and the denominator of which shall be the number of Depositary Shares outstanding immediately after such event.

S-21

Table of Contents

Rights Offerings; pro rata distributions. If we issue Ordinary Share equivalents or rights to purchase shares, warrants, securities or other property pro rata to holders of Depositary Shares, a holder of a warrant will be entitled to acquire, subject to the beneficial ownership limitation described above, such securities or property that such holder could have acquired if such holder had held the number of Depositary Shares issuable upon complete exercise of the warrant immediately prior to the date a record is taken for such issuance. If we declare or make any dividend or other distribution of assets or rights to acquire assets to holders of Depositary Shares or Ordinary Shares, a holder of a warrant will be entitled to participate, subject to the beneficial ownership limitation, in such distribution to the same extent that the holder would have participated therein if the holder had held the number of Depositary Shares issuable upon full exercise of the warrant.

Transferability. Each warrant and all rights thereunder are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment of the warrant subject to applicable securities laws; provided, however, that the Wainwright October Warrants and Wainwright May Warrants are subject to certain FINRA transfer restrictions. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.

No Rights as Shareholder Until Exercise. Except as set forth in the warrants, the holders of the warrants do not have any voting rights, dividends or other rights as a holder of our capital stock until they exercise the warrants.

August 2022 Warrants

On August 3, 2022, we issued warrants to purchase 16,666 Ordinary Shares to Strand Hanson Limited, in payment for services rendered. The exercise price of such warrants is £2.70 per share and they expire three years from the issuance date.

May 2020 United Kingdom Placing Warrants

On May 22, 2020, we issued 333,333 Units, with each Unit comprising one new Ordinary Share and one UK Warrant. The exercise price of the UK Warrants is £6.80 per share and it expires five years and six months from the issuance date. We also issued UK Warrants to purchase a total of 16,666 Ordinary Shares to Turner Pope, the placing agent, in connection with the closing of such offering, on the same terms and conditions as the other investors in the offering.

Series A Warrants, Series B Warrants, Pre-Funded Warrants and Ladenburg Warrants

The following is a brief summary of the Series A warrants, pre-funded warrants and the Ladenburg Warrants issued in connection with the February Private Placement, and is subject in all respects to the provisions contained in the applicable warrants, which, are filed as exhibits to our Report on Form 6-K dated February 9, 2023. Unless otherwise stated, references to warrants in this subsection include the Series A warrants, pre-funded warrants and Ladenburg Warrants. All Series B warrants issued in the February Private Placement have been exercised.

Exercisability. The warrants are exercisable. The Series A warrants expire five years from the initial exercise date and the Ladenburg Warrants expire three years from the initial exercise date. The pre-funded warrants do not expire. The holder shall deliver the aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise (subject to the ‘cashless exercise’ arrangements described below). The pre-funded warrants are exercisable at any time after the initial exercise date until exercised in full and may be exercised on a cashless basis.

S-22

Table of Contents

Cashless Exercise. The Series A warrants may be exercised on a cashless basis. In such event, the aggregate number of Depositary Shares issuable in such cashless exercise pursuant to any given notice of exercise electing to effect an alternative cashless exercise shall equal the product of (x) the aggregate number of Depositary Shares that would be issuable upon exercise of the Series A warrant in accordance with the terms of thereof if such exercise were by means of a cash exercise rather than a cashless exercise and (y) 1.00.

Exercise Price. The exercise price of each (i) Series A warrant and Series B warrant is $2.68 per Depositary Share, (ii) pre-funded warrant is $0.0004 per Depositary Share, and (ii) and a portion of the Ladenburg Warrants are $5.00 per Depositary Share and another portion is $2.90 per Depositary Share, respectively, each subject to the ‘cashless exercise’ arrangements described above and to adjustment as described herein (other than the Ladenburg Warrants).

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder or any such affiliate, would beneficially own in excess of 9.99% (or in the case of the Ladenburg Warrants, 4.99%), of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Depositary Shares upon such exercise. The holder of the warrant, upon notice to us, may increase or decrease the beneficial ownership limitation to a percentage not to exceed 9.99%, provided that any increase in the beneficial ownership limitation shall not be effective until 61 days following notice to us. Beneficial ownership of the holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange Act, and the rules and regulations promulgated thereunder.

Fundamental Transaction. If we effect a fundamental transaction, including, among other things, a merger, sale of substantially all of our assets, tender offer, exchange offer and other business combination transactions, then upon any subsequent exercise of a warrant, the holder thereof shall have the right to receive, for each Ordinary Share represented by the Depositary Shares that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of the successor’s or acquiring corporation’s securities, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction by a holder of the number of Ordinary Shares represented by the Depositary Shares for which the warrant is exercisable immediately prior to such fundamental transaction. In addition, with respect to the Series A warrants, Series B warrants and the Ladenburg Warrants, in the event of a fundamental transaction that is (i) an all cash or substantially all cash transaction, (ii) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (iii) with certain limited exceptions, a fundamental transaction involving a person or entity not traded on a national securities exchange or other established trading market, including, but not limited to, the London Stock Exchange, AIM, The New York Stock Exchange, Inc., The NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market, the OTC QX, the OTC QB or the Over-the-Counter Bulletin Board, then the Company or any successor entity will pay at the holder’s option, exercisable at any time concurrently with or within 30 days after the consummation of the fundamental transaction, an amount of cash equal to the value of the Warrant as determined in accordance with the Black Scholes option pricing model.

S-23

Table of Contents

Transferability. Each warrant and all rights thereunder are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment of the warrant subject to applicable securities laws; provided, however, that the Ladenburg Warrants are subject to certain FINRA transfer restrictions. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.

Articles of Association

Shares and Rights Attaching to Them

Objects

The objects of our Company are unrestricted.

Share Rights

Subject to any special rights attaching to shares already in issue, our shares may be issued with or have attached to them any preferred, deferred or other special rights or privileges or be subject to such restrictions as we may resolve by ordinary resolution of the shareholders or decision of our board.

Voting Rights

Without prejudice to any rights or restrictions as to voting rights attached to any shares forming part of our share capital from time to time, the voting rights attaching to shares are as follows:

on a show of hands every shareholder who is present in person and each duly authorized representative present in person of a shareholder that is a corporation shall have one vote;

on a show of hands, each proxy present in person has one vote for and one vote against a resolution if the proxy has been duly appointed by more than one shareholder and the proxy has been instructed by one or more of those shareholders to vote for the resolution and by one or more other of those shareholders to vote against it;

on a show of hands, each proxy present in person has one vote for and one vote against a resolution if the proxy has been duly appointed by more than one shareholder entitled to vote on the resolution and either: (1) the proxy has been instructed by one or more of those shareholders to vote for the resolution and has been given any discretion by one or more other of those shareholders to vote and the proxy exercises that discretion to vote against it; or (2) the proxy has been instructed by one or more of those shareholders to vote against the resolution and has been given any discretion by one or more other of those shareholders to vote and the proxy exercises that discretion to vote for it; and

on a poll every shareholder who is present in person or by proxy shall have one vote for each share of which he is the holder.

At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is demanded. Subject to the provisions of the Companies Act, a poll may be demanded by:

the chairman of the meeting;

S-24

Table of Contents

at least five shareholders present in person or by proxy and entitled to vote;

any shareholder(s) present in person or by proxy and representing in the aggregate not less than 10% of the total voting rights of all shareholders having the right to vote on the resolution; or

any shareholder(s) present in person or by proxy and holding shares conferring a right to vote on the resolution on which there have been paid up sums in the aggregate equal to not less than 10% of the total sums paid up on all shares conferring that right.

Restrictions on Voting

No shareholder shall be entitled to vote at any general meeting or at any separate class meeting in respect of any share held by him unless all calls or other sums payable by him in respect of that share have been paid.

The Board of Directors may from time to time make calls upon the shareholders in respect of any money unpaid on their shares and each shareholder shall (subject to at least 14 days’ notice specifying the time or times and place of payment) pay at the time or times so specified the amount called on his shares. If a call remains unpaid after it has become due and payable, and the fourteen days’ notice provided by the Board of Directors has not been complied with, any share in respect of which such notice was given may be forfeited by a resolution of the Board of Directors.

A shareholder’s right to attend general or class meetings of the Company or to vote in respect of his shares may be suspended by the Board of Directors in accordance with our Articles of Association if he or she fails to comply with a proper request for the disclosure of interests regarding the shares. See “—Other United Kingdom Law Considerations—Disclosure of Interest in Shares” in this prospectus.

Dividends

We may, by ordinary resolution, declare a dividend to be paid to the share owners according to their respective rights and interests in profits, and may fix the time for payment of such dividend. No dividend may be declared in excess of the amount recommended by the directors. The Board of Directors may from time to time declare and pay to our share owners such interim dividends as appear to the directors to be justified by our profits available for distribution. There are no fixed dates on which entitlement to dividends arises on our ordinary shares.

The share owners may pass, on the recommendation of the directors, an ordinary resolution to direct that all or any part of a dividend to be paid by distributing specific assets, in particular paid up shares or debentures of any other body corporate. Our articles of association also permit, with the prior authority of an ordinary resolution of shareholders, a scrip dividend scheme under which share owners may be given the opportunity to elect to receive fully paid ordinary shares instead of cash, or a combination of shares and cash, with respect to future dividends.

By the way of the exercise of a lien, if a share owner owes us any money relating in any way to shares, the Board of Directors may deduct any of this money from any dividend on any shares held by the share owner, or from other money payable by us in respect of the shares. Money deducted in this way may be used to pay the amount owed to us.

Unclaimed dividends and other money payable in respect of a share can be invested or otherwise used by directors for our benefit until they are claimed. A dividend or other money remaining unclaimed 12 years after it first became due for payment will be forfeited and shall revert to the Company.

A shareholder’s right to receive dividends on his shares may, if they represent more than 0.25% of the issued shares of that class, be suspended by the directors if he or she fails to comply with a proper request for the disclosure of interests regarding the shares. See “—Other United Kingdom Law Considerations—Disclosure of Interests in Shares” in this prospectus.

S-25

Table of Contents

Change of Control

There is no specific provision in our Articles of Association that would have the effect of delaying, deferring or preventing a change of control. We are, however, subject to the provisions of the United Kingdom City Code on Takeovers and Mergers, or the City Code, which contains detailed provisions regulating the timing and manner of any takeover offer for those of the Company’s shares which confer voting rights. See “—Other United Kingdom Law Considerations—City Code on Takeovers and Mergers” in this prospectus.

Variation of Rights

Whenever our share capital is divided into different classes of shares, all or any of the rights attached to any class may be varied or abrogated in such manner (if any) as may be provided by those rights or (in the absence of any such provision) either with the consent in writing of the holders of at least 75% of the issued shares of that class or with the authority of a special resolution passed at a separate general meeting of the holders of the shares of that class.

Alteration of Share Capital and Repurchases

Subject to the provisions of the Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time:

increase our share capital by allotting and issuing new shares in accordance with the our articles of association and any relevant shareholder resolution;

consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than the existing shares;

subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than our existing shares; or

redenominate our share capital or any class of share capital.

Preemptive Rights and New Issuance of Shares

Under the Companies Act, the issuance of equity securities (except shares held under an employees’ share scheme) that are to be paid for wholly in cash must be offered first to the existing holders of equity securities in proportion to the respective nominal amounts (i.e., par values) of their holdings on the same or more favorable terms, unless a special resolution to the contrary has been passed or the articles of association otherwise provide an exclusion from this requirement (which exclusion can be for a maximum of five years after which our shareholders’ approval would be required to renew the exclusion). In this context, “equity securities” means ordinary shares (and would exclude shares that, with respect to dividends or capital, carry a right to participate only up to a specified amount in a distribution), and any and all rights to subscribe for or convert securities into such ordinary shares. This differs from U.S. law, under which shareholders generally do not have pre-emptive rights unless specifically granted in the certificate of incorporation or otherwise.

By way of resolutions passed at our annual general meeting held on June 20, 2022, or 2022 AGM, authorities were given to the directors to allot shares in the Company, or to grant rights to subscribe for or to convert or exchange any security into shares in the Company, up to an aggregate nominal amount of £32,831.14, representing approximately one third of the then issued share capital of the Company, with such authority set to expire 15 months from the date of passing of said resolution or at the conclusion of the annual general meeting of the Company to be held in 2023, whichever is the earlier. Pursuant to the resolutions passed at the 2022 AGM, we were granted authority to allot up to 32,831,140 Ordinary Shares of £0.02 each in the capital of the Company, of which we had authority to allot 9,849,340 Ordinary Shares of £0.02 each in the capital of the Company on a non-pre-emptive basis. Renewal of such authorizations is expected to be sought at each of our annual general meetings.

S-26

Table of Contents

In circumstances where we allot further Ordinary Shares, we have, in the past, had to apply for such new Ordinary Shares to be admitted to trading on AIM, a market operated by the London Stock Exchange plc, or AIM, which in some instances requires the publication of an admission document. On March 24, 2023, at a general meeting, or the March 2023 GM, our shareholders approved the cancellation of the admission of our Ordinary Shares to trading on AIM, or the AIM Cancellation, which became effective April 26, 2023, meaning that trading applications to AIM are no longer be required in respect of any future allotments of ordinary shares, and the adoption of new articles of association in substitution for and to the entire exclusion of the Articles subject to and with effect from the AIM Cancellation, which make a number of changes that are either administrative in nature or reflect certain updates in applicable law or best practice for companies with shares and ADSs admitted to trading on NASDAQ.

By way of resolutions passed at the March 2023 GM, authorities were given to the directors to generally allot shares in the Company, or to grant rights to subscribe for or to convert or exchange any security into shares in the Company, up to an aggregate nominal amount of £2,300,000 with such authority set to expire at the conclusion of the annual general meeting of the Company to be held in 2025. Pursuant to the authority granted at the March 2023 GM, the Company currently has authority to allot up to 115,000,000 ordinary shares on a non-pre-emptive basis.

Transfer of Shares

Any certificated shareholder may transfer all or any of his shares by an instrument of transfer in the usual common form or in any other manner which is permitted by the Companies Act and approved by the Board of Directors. Any written instrument of transfer shall be signed by or on behalf of the transferor and (in the case of a partly paid share) the transferee.

All transfers of uncertificated shares shall be made in accordance with and subject to the provisions of the Uncertificated Securities Regulations 2001 and the facilities and requirements of its relevant system. The Uncertificated Securities Regulations 2001 permit shares to be issued and held in uncertificated form and transferred by means of a computer-based system.

The Board of Directors may decline to register any transfer of any share unless it is:

a fully paid share;

a share on which the Company has no lien;

in respect of only one class of shares;

in favor of a single transferee or not more than four transferees;

duly stamped or duly certificated or otherwise shown the satisfaction of the Board to be exempt from any required stamp duty; or

delivered for registration at our registered office or such other place as the Board of Directors may decide, accompanied by the certificate for the shares to which it relates (other than uncertificated shares) and any other evidence the Board of Directors may reasonably require to provide the title to such share of the transferor.

If the Board of Directors declines to register a transfer it shall, as soon as practicable and in any event within two months after the date on which the transfer is lodged, send to the transferee notice of the refusal, together with reasons for the refusal.

CREST

CREST is a computerized paperless share transfer and settlement system which allows securities to be transferred by electronic means, without the need for a written instrument of transfer. The Articles of Association are consistent with CREST membership and, among other things, allow for the holding and transfer of shares in uncertificated form.

S-27

Table of Contents

Shareholder Meetings

Annual General Meetings

Notice of General Meetings

Subject to certain conditions, holders of Depositary Shares are entitled to receive notices under the terms of the deposit agreement relating to the Depositary Shares. See “Description of American Depositary Shares—Voting Rights” in this prospectus.

Quorum of General Meetings

No business shall be transacted at any general meeting unless a quorum is present, but the absence of a quorum shall not preclude the appointment, choice or election of a chairman which shall not be treated as part of the business of the meeting. At least two shareholders present in person or by proxy and entitled to vote shall be a quorum for all purposes.

Class Meetings

The provisions in the Articles of Association relating to general meetings apply to every separate general meeting of the holders of a class of shares except that:

no member, other than a member of the Board of Directors, shall be entitled to notice of it or attend such meeting unless he is a holder of shares of that class;

the quorum for such class meeting shall be two holders in person or by proxy representing not less than one-third in nominal value of the issued shares of the class;

at the class meeting, a holder of shares of the class present in person or by proxy may demand a poll and shall on a poll be entitled to one vote for every shares of the class held by him; and

if at any adjourned meeting of such holders a quorum is not present at the meeting, one holder of shares of the class present in person or by proxy at an adjourned meeting constitutes a quorum.

Directors

Number of Directors

We may not have less than two directors on our Board of Directors. We have no maximum number of directors, though we may fix a maximum number by ordinary resolution of the shareholders. We may, by ordinary resolution of the shareholders, vary the minimum and any maximum number of directors from time to time.

Appointment of Directors

Subject to the provisions of the Articles of Association, we may, by ordinary resolution of the shareholders, elect any person to be a director, either to fill a casual vacancy or as an addition to the existing board.

Without prejudice to the power to appoint any person to be a director by shareholder resolution, the Board of Directors has the power to appoint any person to be a director, either to fill a casual vacancy or as an addition to the existing Board of Directors. Any director appointed by the Board of Directors will hold office only until the earlier to occur of the close of the next following annual general meeting and someone being appointed in his stead at that meeting. Such a director is eligible for re-election at that meeting but shall not be taken into account in determining the directors or the number of directors who are to retire by rotation at such meeting.

S-28

Table of Contents

Rotation of Directors

At every annual general meeting, one-third of the directors or, if their number is not a multiple of three, then the number nearest to and not exceeding one-third, shall retire from office and each director must retire from office at least once every three years. If there are fewer than three directors, one director shall make himself or herself available for re-election

The directors to retire on each occasion shall be those subject to retirement by rotation who have been longest in office since their last election, but as between persons who became or were re-elected directors on the same day those to retire shall (unless they otherwise agree amongst themselves) be determined by lot.

A director who retires at the annual general meeting shall be eligible for re-election.

The shareholders may, at the meeting at which a director retires, fill the vacated office by electing a person and in default the retiring director shall, if willing to continue to act, be deemed to have been re-elected, unless at such meeting it is expressly resolved not to fill such vacated office or unless a resolution for the re-election of such director shall have been put to the meeting and lost or such director has given notice in writing to us that he is unwilling to be re-elected or such director has attained the retirement age applicable to him as director pursuant to the Companies Act.

Director’s Interests

The Board of Directors may authorize, to the fullest extent permitted by law, any matter proposed to them which would otherwise result in a director infringing his duty to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly may conflict, with our interests and which may reasonably be regarded as likely to give rise to a conflict of interest. A director shall not, save as otherwise agreed by him, be accountable to us for any benefit which he (or a person connected with him) derives from any matter authorized by the directors and any contract, transaction or arrangement relating thereto shall not be liable to be avoided on the grounds of any such benefit.

Subject to the requirements under Sections 175, 177 and 182 of the Companies Act (which require a director to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with our interests, and to declare any interest that he has, whether directly or indirectly, in a proposed or existing transaction or arrangement with us), and provided that he has disclosed to the Board of Directors the nature and extent of any interest of his in accordance with the Companies Act and the Articles of Association, a director notwithstanding his office:

may be a party to, or otherwise interested in, any transaction or arrangement with us or in which we are otherwise interested;

may be a director or other officer of, or employed by, or a party to any transaction or arrangement with, or otherwise interested in, any body corporate promoted by us or in which we are otherwise interested; and

shall not, by reason of his office, be accountable to us for any benefit which he derives from any such office or employment or from any such transaction or arrangement or from any interest in any such body corporate and no such transaction or arrangement shall be liable to be avoided on the ground of any such interest or benefit.

In the case of interests arising where a director is in any way, directly or indirectly, interested in (a) a proposed transaction or arrangement with us or (b) a transaction or arrangement that has been entered into by us and save as otherwise provided by the Articles of Association, such director shall not vote at a meeting of the Board of Directors or of a committee of the Board of Directors on any resolution concerning such matter in which he has a material interest (otherwise than by virtue of his interest in shares, debentures or other securities of, or otherwise in or through, us) unless his interest or duty arises only because the case falls within one or more of the following paragraphs:

the resolution relates to the giving to him or a person connected with him of a guarantee, security or indemnity in respect of money lent to, or an obligation incurred by him or such a person at the request of or for the benefit of, us or any of our subsidiaries;

S-29

Table of Contents

the resolution relates to the giving of a guarantee, security or indemnity in respect of a debt or obligation of ours or any of our subsidiaries for which the director or a person connected with him has assumed responsibility in whole or part under a guarantee or indemnity or by the giving of security;

the resolution relates in any way to any other company in which he is interested, directly or indirectly and whether as an officer or shareholder or otherwise howsoever, provided that he and any persons connected with him do not to his knowledge hold an interest in shares representing one per cent or more of any class of the equity share capital of such company or of the voting rights available to shareholder of such company;

the resolution relates in any way to an arrangement for the benefit of our employees or any employees of our subsidiaries which does not award him as such any privilege or benefit not generally awarded to the employees to whom such arrangement relates;

the resolution relates in any way to the purchase or maintenance for the directors of insurance; or

the resolution is in respect of any matter in which the interest of the director cannot reasonably be regarded as conflicting.

A director shall not be counted in the quorum present at a meeting in relation to a resolution on which he is not entitled to vote.

If a question arises at a meeting of the Board of Directors or of a committee of the Board of Directors as to the right of a director to vote or be counted in the quorum, and such question is not resolved by his voluntarily agreeing to abstain from voting or not to be counted in the quorum, the question may, before the conclusion of the meeting, be referred to the chairman of the meeting and his ruling in relation to any director other than himself shall be final and conclusive except in a case where the nature or extent of the interest of the director concerned has not been fairly disclosed.

An interest of a person connected with a director shall be treated as an interest of the director and Section 252 of the Companies Act shall determine whether a person is connected with a director.

Directors’ Fees and Remuneration

Each of the directors shall be paid a fee at such rate as may from time to time be determined by the Board of Directors (or for the avoidance of doubt any duly authorized committee of the Board of Directors) provided that the aggregate of all such fees so paid to directors shall not exceed £600,000 per annum, or such higher amount as may from time to time be determined by ordinary resolution of shareholders.

Each director may be paid his reasonable traveling, hotel and other expenses of attending and returning from meetings of the Board of Directors or committees thereof of or general meetings or separate meetings of the holders class of shares or of debentures and shall be paid all expenses properly and reasonably incurred by him in the conduct of the Company’s business or in the discharge of his duties as a director. Any director who, by request, goes or resides abroad for any purposes required by us or who performs services which in the opinion of the Board of Directors go beyond the ordinary duties of a director may be paid such extra remuneration as the Board of Directors may determine.

An executive director shall receive such remuneration as the Board of Directors may determine, and either in addition to or in lieu of his remuneration as a director as detailed above.

Age Limitations and Share Ownership

We do not have any age limitations for our directors, nor do we have mandatory retirement as a result of reaching a certain age. Our directors are not required to hold any shares in the Company.

S-30

Table of Contents

Borrowing Power

Our directors may exercise all the powers of the Company to borrow or raise money and mortgage or charge all or any part of our undertaking, property and assets (present and future), and uncalled capital. Subject to the Companies Act, the directors may also create and issue debentures, other loan stock and other securities, whether outright or as collateral security for any debt, liability or obligation of the Company or of any third party. Our directors are required to restrict the borrowings of the Company to ensure that the aggregate principal amount of borrowings at any one time outstanding and all of its subsidiary undertakings (other than intra-Group borrowing) shall not at any time, without the previous sanction of an ordinary resolution of the Company, exceed two times the gross asset value of the Company and our subsidiaries.

Liability of Biodexa and its Directors and Officers

Subject to the provisions on indemnities set out in Companies Act, every director, alternate director or former director (and of any associated company) shall be entitled to be indemnified out of our assets against all costs and liabilities incurred by him or her in relation to any proceedings or any regulatory investigation or action which relate to anything done or omitted or alleged to have been done or omitted by him or her as a director so long as the indemnities do not cover liability for breach of duty to the Company or cover any fine, costs or related expense in connection with any proceedings for default on the part of the director. Lawful indemnities extend to the provision of funds to him or her by the Company to meet expenditure incurred or to be incurred by him in defending himself in any proceedings (whether civil or criminal) or in connection with an application for statutory relief or in an investigation by a regulatory authority which must however be repaid where such proceedings, application, investigation or action are in connection with any alleged negligence, default, breach of duty or breach of trust by him or her in relation to the Company (or any associated company of ours) and he or she is convicted or found in default thereof. Under English law, any provision that purports to exempt a director of a company (to any extent) from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.

Under a deed poll declared by us on August 5, 2015, or a Deed of Indemnity, our Board of Directors and our Company Secretary are indemnified against costs and liabilities incurred in connection with their office, other than any liability owed by such person to the Company itself (or any of our associated entities) and other than indemnification for liabilities in certain circumstances, which are prohibited by virtue of the Companies Act. The Deed of Indemnity provides that a director may also be lent sums to finance any relevant defense costs, provided that, in the event such proceedings involve criminal or civil matters in which the person is convicted or has a judgment made against him or her, then such loan must be repaid. Our total aggregate liability of Biodexa under the Deed of Indemnity is £5 million.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to a charter provision, by-law, contract, arrangements, statute or otherwise, we acknowledge that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

Other United Kingdom Law Considerations

Mandatory Purchases and Acquisitions

Pursuant to Sections 979 to 991 of the Companies Act, where a takeover offer has been made for us and the offeror has acquired or unconditionally contracted to acquire not less than 90% in value of the shares to which the offer relates and not less than 90% of the voting rights carried by those shares, the offeror may give notice to the holder of any shares to which the offer relates which the offeror has not acquired or unconditionally contracted to acquire that he wishes to acquire, and is entitled to so acquire, those shares on the same terms as the general offer. The offeror would do so by sending a notice to the outstanding minority shareholders telling them that it will compulsorily acquire their shares. Such notice must be sent within three months of the last day on which the offer can be accepted in the prescribed manner. The squeeze-out of the minority shareholders can be completed at the end of six weeks from the date the notice has been given, following which the offeror can execute a transfer of the outstanding shares in its favor and pay the consideration to us, and we would hold the consideration on trust for the outstanding minority shareholders. The consideration offered to the outstanding minority shareholders whose shares are compulsorily acquired under the Companies Act must, in general, be the same as the consideration that was available under the takeover offer.

S-31

Table of Contents

Sell Out

The Companies Act also gives our minority shareholders a right to be bought out in certain circumstances by an offeror who has made a takeover offer for all of our shares. The holder of shares to which the offer relates, and who has not otherwise accepted the offer, may require the offeror to acquire his shares if, prior to the expiry of the acceptance period for such offer, (i) the offeror has acquired or agreed to acquire not less than 90% in value of the voting shares, and (ii) not less than 90% of the voting rights carried by those shares. The offeror may impose a time limit on the rights of minority shareholders to be bought out that is not less than three months after the end of the acceptance period. If a shareholder exercises his rights to be bought out, the offeror is required to acquire those shares on the terms of this offer or on such other terms as may be agreed.

Disclosure of Interest in Shares

Pursuant to Part 22 of the Companies Act, we are empowered by notice in writing to any person whom we know or have reasonable cause to believe to be interested in our shares, or at any time during the three years immediately preceding the date on which the notice is issued has been so interested, requiring such person within a reasonable time to disclose to us particulars of that person’s interest and (so far as is within his knowledge) particulars of any other interest that subsists or subsisted in those shares. The Articles of Association specify that a response is required from such person within 14 days after service of any such notice.

Under the Articles of Association, if a person defaults in supplying us with the required particulars in relation to the shares in question, or Default Shares, the directors may by notice direct that:

in respect of the Default Shares, the relevant member shall not be entitled to attend or vote (either in person or by proxy) at any general meeting or of a general meeting of the holders of a class of shares or upon any poll or to exercise any right conferred by the Default Shares; and/or

where the Default Shares represent at least 0.25% of their class, (a) any dividend (or any part of a dividend) payable in respect of the Default Shares shall be retained by us without liability to pay interest, (b) the shareholder may not be entitled to elect to receive shares instead of a dividend, and (c) no transfers by the relevant member of any Default Shares may be registered (unless the member himself is not in default and the transfer does not relate to Default Shares, the transfer is exempt or that the transfer is permitted under the U.K. Uncertificated Securities Regulations 2001).

Purchase of Own Shares

Under English law, a limited company may only purchase or redeem its own shares out of the distributable profits of the company or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, provided that they are not restricted from doing so by their articles. A limited company may not purchase or redeem its own shares if, as a result of the purchase, there would no longer be any issued shares of the company other than redeemable shares or shares held as treasury shares. Shares must be fully paid in order to be repurchased.

Subject to the above, we may purchase our own shares in the manner prescribed below. We may make a market purchase of our own fully paid shares pursuant to an ordinary resolution of shareholders. The resolution authorizing the purchase must:

specify the maximum number of shares authorized to be acquired;

determine the maximum and minimum prices that may be paid for the shares; and

specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire.

S-32

Table of Contents

We may purchase our own fully paid shares otherwise than on a recognized investment exchange pursuant to a purchase contract authorized by resolution of shareholders before the purchase takes place. Any authority will not be effective if any shareholder from whom we propose to purchase shares votes on the resolution and the resolution would not have been passed if he had not done so. The resolution authorizing the purchase must specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire.

Distributions and Dividends

Under the Companies Act, before a company can lawfully make a distribution or dividend, it must ensure that it has sufficient distributable reserves (on a non-consolidated basis). The basic rule is that a company’s profits available for the purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution or capitalization, less its accumulated, realized losses, so far as not previously written off in a reduction or reorganization of capital duly made. The requirement to have sufficient distributable reserves before a distribution or dividend can be paid applies to us and to each of our subsidiaries that has been incorporated under English law.

It is not sufficient that we, as a public company, have made a distributable profit for the purpose of making a distribution. An additional capital maintenance requirement is imposed on us to ensure that the net worth of the company is at least equal to the amount of its capital. A public company can only make a distribution:

if, at the time that the distribution is made, the amount of its net assets (that is, the total excess of assets over liabilities) is not less than the total of its called up share capital and undistributable reserves; and

if, and to the extent that, the distribution itself, at the time that it is made, does not reduce the amount of the net assets to less than that total.

City Code on Takeovers and Mergers

Following the AIM Cancellation, we remain a public limited company incorporated in, and with our registered office in, the United Kingdom but our securities will not be admitted to trading on a regulated market or multilateral trading facility in the United Kingdom (or a stock exchange in the Channel Islands or the Isle of Man). The City Code will then only apply to us if we are considered by the United Kingdom Panel on Takeovers and Mergers, or the Panel, to have our place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the “residency test”. The way in which the test for central management and control is applied for the purposes of the City Code may be different from the way in which it is applied by the United Kingdom tax authorities, HMRC. Under the City Code, the Panel typically considers where the majority of the directors of the Company are resident, amongst other factors, for the purposes of determining where the Company has its place of central management and control.

Immediately following the AIM Cancellation, three of our four directors will be resident in the United Kingdom and our place of central management and control is intended, for the time being, to remain in the United Kingdom. Accordingly, the Panel has confirmed that, following the AIM Cancellation, we will continue to be subject to the City Code, and the Company and its shareholders will therefore continue to have the benefit of the protections that the City Code affords, including, but not limited to, under Rule 9 of the City Code as set out above.

The City Code is issued and administered by the Panel. The City Code provides a framework within which takeovers of companies subject to it are conducted. In particular, the City Code contains certain rules in respect of mandatory offers. Under Rule 9 of the City Code, if a person:

acquires an interest in our shares which, when taken together with shares in which he or persons acting in concert with him are interested, carries 30% or more of the voting rights of our shares; or

S-33

Table of Contents

the acquirer, and depending on the circumstances, its concert parties would be required (except with the consent of the Panel) to make a cash offer for our outstanding shares at a price not less than the highest price paid for any interests in the shares by the acquirer or its concert parties during the previous 12 months.

Notwithstanding the above, we may cease to be subject to the City Code in the future if there are any changes that lead to us being deemed to no longer have its place of central management and control in the United Kingdom, Channel Islands or the Isle of Man.

Exchange Controls

There are no governmental laws, decrees, regulations or other legislation in the United Kingdom that may affect the import or export of capital, including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends, interest, or other payments by us to non-resident holders of our Ordinary Shares or Depositary Shares, other than withholding tax requirements. There is no limitation imposed by English law or in the Articles of Association on the right of non-residents to hold or vote shares.

S-34

Table of Contents

description of american depositary shares

General

Our Depositary Shares are deposited pursuant to the Amended and Restated Deposit Agreement dated February 8, 2021, among the Company, The Bank of New York Mellon as depositary, ands owners and holders of Depositary Shares. The depositary registers and delivers the Depositary Shares. Each Depositary Share represents five Ordinary Shares (or a right to receive five Ordinary Shares) deposited with The Bank of New York Mellon, London Branch, or any successor, as custodian for the depositary. Each Depositary Share also represents any other securities, cash or other property that may be held by the depositary. The deposited Ordinary Shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary’s office at which the Depositary Shares are administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.

You may hold Depositary Shares either (1) directly (a) by having an American Depositary Receipt, or ADR, which is a certificate evidencing a specific number of Depositary Shares, registered in your name, or (b) by having Depositary Shares registered in your name in the Direct Registration System, or (2) indirectly by holding a security entitlement in Depositary Shares through your broker or other financial institution. If you hold Depositary Shares directly, you are a registered Depositary Share holder, also referred to as an ADS holder. This description assumes you are a Depositary Share holder. If you hold the Depositary Shares indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of Depositary Share holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.

The Direct Registration System, or DRS, is a system administered by The Depository Trust Company, or DTC, pursuant to which the depositary may register the ownership of uncertificated Depositary Shares, which ownership is confirmed by periodic statements sent by the depositary to the registered holders of uncertificated Depositary Shares.

Depositary Share holders are not treated as shareholders and do not have shareholder rights. English law governs shareholder rights. The depositary is the holder of the ordinary shares underlying the Depositary Shares. As a holder of Depositary Shares, you will have Depositary Share holder rights. A deposit agreement among us, the depositary and you, as a Depositary Share holder, and all other persons directly and indirectly holding Depositary Shares sets out Depositary Share holder rights as well as the rights and obligations of the depositary. A copy of the deposit agreement is incorporated by reference as an exhibit to the Company’s 2022 Annual Report. New York law governs the deposit agreement and the Depositary Shares.

The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of Depositary Share.

Dividends and Other Distributions

How will you receive dividends and other distributions on the Ordinary Shares?

The depositary has agreed to pay you the cash dividends or other distributions it or the custodian receives on Ordinary Shares or other deposited securities, after deducting its fees and expenses. As a Depositary Share holder, you will receive these distributions in proportion to the number of Ordinary Shares your Depositary Shares represent.

Cash. We do not expect to declare or pay any cash dividends or cash distributions on our Ordinary Shares for the foreseeable future. The depositary will convert any cash dividend or other cash distribution we pay on the Ordinary Shares or any net proceeds from the sale of any Ordinary Shares, rights, securities or other entitlements into U.S. dollars if it can do so on a reasonable basis and at the then prevailing market rate, and can transfer the U.S. dollars to the United States. If that is not possible and lawful or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those Depositary Share holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the Depositary Share holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. Before making a distribution, any taxes or other governmental charges, together with fees and expenses of the depositary that must be paid, will be deducted. See the section titled “Item 10 E. Additional Information—Taxation” in our 2022 Annual Report for a summary of certain tax consequences in respect of dividends or distributions to holders of Depositary Shares. It will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.

S-35

Table of Contents

Ordinary Shares. The depositary may distribute additional Depositary Shares representing any Ordinary Shares we distribute as a dividend or free distribution to the extent reasonably practicable and permissible under law. The depositary will only distribute whole Depositary Shares. If the depositary does not distribute additional Depositary Shares, the outstanding Depositary Shares will also represent the new Ordinary Shares. The depositary may sell a portion of the distributed Ordinary Shares sufficient to pay its fees and expenses in connection with that distribution.

Elective Distributions in Cash or Shares. If we offer holders of our Ordinary Shares the option to receive dividends in either cash or shares, the depositary, after consultation with us, may make such elective distribution available to you as a holder of the Depositary Shares. We must first instruct the depositary to make such elective distribution available to you. As a condition of making a distribution election available to Depositary Share holders, the depositary may require satisfactory assurances from us that doing so would not require registration of any securities under the Securities Act. There can be no assurance that you will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of Ordinary \Shares, or at all.

Rights to Purchase Additional Ordinary Shares. If we offer holders of our securities any rights to subscribe for additional Ordinary Shares or any other rights, the depositary may make these rights available Depositary Share holders. If the depositary decides it is not legal and practical to make the rights available but that it is practical to sell the rights, the depositary will use reasonable efforts to sell the rights and distribute the proceeds in the same way as it does with cash distributions. The depositary will allow rights that are not distributed or sold to lapse. In that case, you will receive no value for them.

If the depositary makes rights available to you, it will exercise the rights and purchase the Ordinary Shares on your behalf and in accordance with your instructions. The depositary will then deposit the ordinary shares and deliver Depositary Shares to you. It will only exercise rights if you pay it the exercise price and any other charges the rights require you to pay and comply with other applicable instructions.

U.S. securities laws may restrict transfers and cancellation of the Depositary Shares representing Ordinary Shares purchased upon exercise of rights. For example, you may not be able to trade these Depositary Shares freely in the United States. In this case, the depositary may deliver restricted Depositary Shares that have the same terms as the Depositary Shares described in this section except for changes needed to put the necessary restrictions in place.

Other Distributions. The depositary will send to you anything else we distribute to holders of deposited securities by any means it determines is equitable and practicable. If it cannot make the distribution proportionally among the owners, the depositary may adopt another equitable and practical method. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case Depositary Shares will also represent the newly distributed property.

However, the depositary is not required to distribute any securities (other than Depositary Shares) to Depositary Share holders unless it receives satisfactory evidence from us that it is legal to make that distribution. In addition, the depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution.

Neither we nor the depositary are responsible for any failure to determine that it may be lawful or feasible to make a distribution available to any Depositary Share holders. We have no obligation to register Depositary Shares, ordinary shares, rights or other securities under the Securities Act. This means that you may not receive the distributions we make on our Ordinary Shares or any value for them if it is illegal or impractical for us to make them available to you.

S-36

Table of Contents

Deposit, Withdrawal and Cancellation

How are Depositary Shares issued?

The depositary will deliver Depositary Shares if you or your broker deposit Ordinary Shares or evidence of rights to receive Ordinary Shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, and delivery of any required endorsements, certifications or other instruments of transfer required by the depositary, the depositary will register the appropriate number of Depositary Shares in the names you request and will deliver the Depositary Shares to or upon the order of the person or persons that made the deposit.

How can Depositary Share holders withdraw the deposited securities?

You may surrender your Depositary Shares at the depositary’s corporate trust office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, the depositary will transfer and deliver the Ordinary Shares and any other deposited securities underlying the Depositary Shares to you or a person designated by you at the office of the custodian or through a book-entry delivery. Alternatively, at your request, risk and expense, the depositary will transfer and deliver the deposited securities at its corporate trust office, if feasible.

How do Depositary Share holders interchange between certificated Depositary Shares and uncertificated Depositary Shares?

You may surrender your ADRs to the depositary for the purpose of exchanging your ADRs for uncertificated Depositary Shares. The depositary will cancel the ADRs and will send you a statement confirming that you are the owner of uncertificated Depositary Shares. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated Depositary Shares requesting the exchange of uncertificated Depositary Shares for certificated Depositary Shares, the depositary will execute and deliver to you an ADR evidencing those Depositary Shares.

Voting Rights

How do you vote?

You may instruct the depositary to vote the number of whole deposited Ordinary Shares your Depositary Shares represent. The depositary will notify you of shareholders’ meetings or other solicitations of consents and arrange to deliver our voting materials to you if we ask it to. Those materials will describe the matters to be voted on and explain how you may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary.

The depositary will try, as far as practical, and subject to the laws of England and Wales and our Articles of Association, to vote or to have its agents vote the Ordinary Shares or other deposited securities as instructed by Depositary Share holders.

The depositary will only vote or attempt to vote as you instruct or as described above. If we ask the depositary to solicit the Depositary Share holders’ instructions to vote and a Depositary Share holder fails to instruct the depositary as to the manner in which to vote by the specified date, such Depositary Share holder will be deemed to have given a discretionary proxy to a person designated by us to vote the number of deposited securities represented by its Depositary Shares, unless we notify the depositary that we do not wish to receive a discretionary proxy, there is substantial shareholder opposition to the particular question, or the particular question would have an adverse impact on our shareholders.

We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your Ordinary Shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions provided that any such failure is in good faith. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your Ordinary Shares are not voted as you requested.

S-37

Table of Contents

In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we will try to give the depositary notice of any such meeting and details concerning the matters to be voted upon sufficiently in advance of the meeting date.

Except as described above, you will not be able to exercise your right to vote unless you withdraw the Ordinary Shares. However, you may not know about the shareholder meeting far enough in advance to withdraw the Ordinary |Shares.

Fees and Expenses

What fees and expenses will you be responsible for paying?

Pursuant to the terms of the deposit agreement, the holders of Depositary Shares will be required to pay the following fees:

Persons depositing or withdrawing our ordinary shares or depositary share holders must pay:		*For:*
5.00 USD (or less) per 100 Depositary Shares (or portion of 100 Depositary Shares)		Issue of Depositary Shares, including issues resulting from a distribution of our ordinary shares or rights or other property
		Cancellation of Depositary Shares for the purpose of withdrawal, including if the deposit agreement terminates
0.05 USD (or less) per Depositary Share		Any cash distribution to Depositary Share holders
A fee equivalent to the fee that would be payable if securities distributed to Depositary Share holders had been our Ordinary Shares and the Ordinary Shares had been deposited for issuance of Depositary Shares		Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to Depositary Share holders
0.05 USD (or less) per Depositary Share per calendar year		Depositary services
Registration or transfer fees		Transfer and registration of shares of our Ordinary Shares on our share register to or from the name of the depositary or its agent when persons deposit or withdraw our Ordinary Shares
Expenses of the Depositary		Cable and facsimile transmissions (when expressly provided in the deposit agreement)
		Converting foreign currency to U.S. dollars
Taxes and other governmental charges the depositary or the custodian has to pay on any Depositary Share or our Ordinary Shares underlying Depositary Shares, such as stock transfer taxes, stamp duty or withholding taxes		As necessary
Any charges incurred by the depositary or its agents for servicing the deposited securities		As necessary

The depositary collects its fees for delivery and surrender of Depositary Shares directly from investors depositing our Ordinary Shares or surrendering Depositary Shares for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to Depositary Share holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

S-38

Table of Contents

In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.

The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to Depositary Share holders, subject to the depositary’s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.

The depositary has agreed to reimburse us for a portion of certain expenses it incurs that are related to establishment and maintenance of the ADR program. There are limits on the amount of expenses for which the depositary will reimburse us, but the amount of reimbursement available to us is not related to the amounts of fees the depositary collects from investors. Further, the depositary has agreed to reimburse us certain fees payable to the depositary by holders of Depositary Shares. Neither we nor the depositary can determine the exact amount to be made available to us because (i) the number of Depositary Shares that will be issued and outstanding, (ii) the level of service fees to be charged to holders of Depositary Shares and (iii) its reimbursable expenses related to the program are not known at this time.

Payment of Taxes

Depositary Share holders will be responsible for any taxes or other governmental charges payable on their Depositary Shares or on the deposited securities represented by any of their Depositary Shares. The depositary may refuse to register any transfer of Depositary Shares or allow a Depositary Share holder to withdraw the deposited securities represented by his or her Depositary Shares until those taxes or other charges are paid. It may apply payments owed to such Depositary Share holder or sell deposited securities represented by such Depositary Share holder’s Depositary Shares to pay any taxes owed and such Depositary Share holder will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of Depositary Shares to reflect the sale and pay to Depositary Share holders any proceeds, or send to Depositary Share holders any property, remaining after it has paid the taxes.

Reclassifications, Recapitalizations and Mergers

*If we:*			*Then:*
	·	Change the nominal or par value of our Ordinary Shares	The cash, Ordinary Shares or other securities received by the depositary will become deposited securities.
	·	Reclassify, split up or consolidate any of the deposited securities	Each Depositary Share will automatically represent its equal share of new deposited securities.
	·	Distribute securities on the Ordinary Shares that are not distributed to you	The depositary may also deliver new Depositary Shares or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. The depositary may also sell the new deposited securities and distribute the net proceeds if we are unable to assure the depositary that the distribution (a) does not require registration under the Securities Act or (b) is exempt from registration under the Securities Act.
	·	Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action	Any replacement securities received by the depositary shall be treated as newly deposited securities and either the existing Depositary Shares or, if necessary, replacement Depositary Shares distributed by the depositary will represent the replacement securities. The depositary may also sell the replacement securities and distribute the net proceeds if the replacement securities may not be lawfully distributed to all Depositary Share holders.

S-39

Table of Contents

Amendment and Termination

How may the deposit agreement be amended?

We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of Depositary Share holders, it will not become effective for outstanding Depositary Shares until 30 days after the depositary notifies Depositary Share holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your Depositary Shares, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.

How may the deposit agreement be terminated?

The depositary will terminate the deposit agreement at our direction by mailing notice of termination to the Depositary Share holders then outstanding at least 30 days prior to the date fixed in such notice for such termination. The depositary may also terminate the deposit agreement by mailing a notice of termination to us and the Depositary Share holders if 60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment.

After termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect distributions on the deposited securities, sell rights and other property, and deliver Ordinary Shares and other deposited securities upon cancellation of Depositary Shares. Four months after termination, the depositary may sell any remaining deposited securities by public or private sale. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement for the pro rata benefit of the Depositary Share holders that have not surrendered their Depositary Shares. It will not invest the money and has no liability for interest. The depositary’s only obligations will be to account for the money and other cash. After termination our only obligations under the deposit agreement will be to indemnify the depositary and to pay fees and expenses of the depositary that we agreed to pay and we will not have any obligations thereunder to current or former Depositary Share holders.

Limitations on Obligations and Liability

Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of Depositary Shares

The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:

are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;

are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement;

are not liable if we or it exercises discretion permitted under the deposit agreement;

are not liable for the inability of any holder of Depositary Shares to benefit from any distribution on deposited securities that is not made available to holders of Depositary Shares under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;

S-40

Table of Contents

have no obligation to become involved in a lawsuit or other proceeding related to the Depositary Shares or the deposit agreement on your behalf or on behalf of any other person;

may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person;

are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and

the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by Depositary Share holders as a result of owning or holding Depositary Shares or be liable for the inability or failure of a Depositary Share holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit.

In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. Additionally, we, the depositary and each owner and holder, to the fullest extent permitted by applicable law, waive the right to a jury trial in an action against us or the depositary arising out of or relating to the deposit agreement.

Requirements for Depositary Actions

Before the depositary will deliver or register a transfer of Depositary Shares, make a distribution on Depositary Shares, or permit withdrawal of Ordinary Shares, the depositary may require:

payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities;

satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and

compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.

The depositary may refuse to deliver Depositary Shares or register transfers of Depositary Shares when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.

Your Right to Receive the Ordinary Shares Underlying your Depositary Shares

Depositary Share holders have the right to cancel their Depositary Shares and withdraw the underlying Ordinary Shares at any time except:

when temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of Ordinary Shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our Ordinary Shares;

when you owe money to pay fees, taxes and similar charges; or

when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to Depositary Shares or to the withdrawal of Ordinary Shares or other deposited securities.

This right of withdrawal may not be limited by any other provision of the deposit agreement.

S-41

Table of Contents

Pre-release of Depositary Shares

The deposit agreement permits the depositary to deliver Depositary Shares before deposit of the underlying Ordinary Shares. This is called a pre-release of the Depositary Shares. The depositary may also deliver Ordinary Shares upon cancellation of pre-released Depositary Shares (even if the Depositary Shares are canceled before the pre-release transaction has been closed out). A pre-release is closed out as soon as the underlying Ordinary Shares are delivered to the depositary.

The depositary may receive Depositary Shares instead of Ordinary Shares to close out a pre-release. The depositary may pre-release Depositary Shares only under the following conditions: (1) before or at the time of the pre-release, the person to whom the pre-release is being made represents to the depositary in writing that it or its customer owns the ordinary shares or Depositary Shares to be deposited; (2) the pre-release is fully collateralized with cash or other collateral that the depositary considers appropriate; and (3) the depositary must be able to close out the pre-release on not more than five business days’ notice. In addition, the depositary will limit the number of Depositary Shares that may be outstanding at any time as a result of prerelease to 30% of the number of deposited shares, although the depositary may disregard this limit from time to time if it determines it is appropriate to do so.

Direct Registration System

In the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile, will apply to uncertificated Depositary Shares upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the depositary may register the ownership of uncertificated Depositary Shares and such ownership will be evidenced by periodic statements sent by the depositary to the registered holders of uncertificated Depositary Shares. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of Depositary Shares, to direct the depositary to register a transfer of those Depositary Shares to DTC or its nominee and to deliver those Depositary Shares to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the Depositary Share holder to register that transfer.

In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an Depositary Share holder in requesting registration of transfer and delivery described in the paragraph above has the actual authority to act on behalf of the Depositary Share holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary’s reliance on and compliance with instructions received by the depositary through the DRS/Profile System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.

Shareholder Communications; Inspection of Register of Holders of Depositary Shares

The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of Depositary Shares, but not for the purpose of contacting those holders about a matter unrelated to our business or the Depositary Shares.

S-42

Table of Contents

TAXATION

A summary of the material United Kingdom tax considerations and material United States federal income tax consequences relating to the purchase, ownership and disposition of the Registered Depositary Shares offered by this prospectus supplement is contained in our most recent Annual Report on Form 20-F and in the other filings we make with the SEC, from time to time, which are incorporated by reference into this prospectus supplement.

S-43

Table of Contents

PLAN OF DISTRIBUTION

Pursuant to a placement agency agreement dated as of May 23, 2023, we have engaged Ladenburg Thalmann & Co. Inc., or the placement agent, to act as our exclusive placement agent in connection with this offering. Under the terms of the placement agency agreement, the placement agent has agreed to act on a reasonable best efforts basis, in connection with the issuance and sale by us of our Depositary Shares in this takedown from our shelf registration statement. The terms of this offering were subject to market conditions and negotiations between us, the placement agent and prospective investors. The placement agency agreement does not give rise to any commitment by the placement agent to purchase any of our Registered Depositary Shares, and the placement agent will have no authority to bind us by virtue of the placement agency agreement. Further, the placement agent does not guarantee that it will be able to raise a specific amount of capital in this offering. The placement agent may engage sub-agents or selected dealers to assist with the offering.

The placement agent proposes to arrange for the sale of the Registered Depositary Shares we are offering pursuant to this prospectus supplement and accompanying prospectus to the investors through a securities purchase agreement directly between the investors and us.

We expect to deliver the Registered Depositary Shares being offered pursuant to this prospectus supplement on or about May 26, 2023, subject to satisfaction of certain closing conditions.

We have agreed to pay the placement agent a total cash fee equal to 8.0% of the aggregate gross proceeds of this offering. We will also pay the placement agent a management fee equal to 1.0% of the gross proceeds raised in the offering and an expense allowance of up to an aggregate of $85,000 for legal fees and other out-of-pocket expenses. We estimate the total expenses payable by us for this offering will be approximately $[ ] million, including approximately $[ ] for the offering of the Registered Depositary Shares, and which amount also includes the placement agent’s fees and reimbursable expenses. In addition, we have agreed to issue to the placement agent warrants to purchase up to 4.0% of the aggregate number of Depositary Shares (or Depositary Share equivalents) sold in the offering. The placement agent warrant has substantially the same terms as the Series D Warrants issued to the investors in this offering, except that the exercise price of the placement agent warrant will be $0.1875 and the placement agent warrant terminates three years from the initial exercise date, and except as required by FINRA.

We also have granted the placement agent a tail fee equal to the cash fee and warrant compensation set forth above in connection with any public or private offering or capital raising transaction within twelve (12) months following the termination of the engagement letter in which the capital or financing is provided by the investor which the placement agent contacted or introduced to us during the term of the engagement letter.

In addition, we have granted a right of first refusal to the placement agent pursuant to which it has the right to act as the sole bookrunner or exclusive placement agent or exclusive sales agent, as applicable, if we or our subsidiaries raise capital through a public or private offering of equity or debt securities at any time prior to the twelve (12) month anniversary of the closing date of the offering.

We have agreed to indemnify the placement agent and specified other persons against certain liabilities relating to or arising out of the placement agent’s activities under the engagement letter agreement, including liabilities under the Securities Act, and to contribute to payments that the placement agent may be required to make in respect of such liabilities.

S-44

Table of Contents

Certain investors in this offering entered into leak-out agreements wherein each investor who is party thereto (together with certain of its affiliates) agreed not to sell, dispose or otherwise transfer, directly or indirectly (including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales or short positions), on any trading day, Ordinary Shares and/or ADSs, including ADSs purchased in this offering and the ADSs issuable upon exercise of the Warrants, in an amount more than a specified percentage of the trading volume of the ADSs on the principal trading market, subject to certain exceptions until May 30, 2023. This restriction will not apply to sales or transfers of any such ADSs in transactions which do not need to be reported on the Nasdaq consolidated tape so long as the purchaser or transferee executes and delivers a leak-out agreement. After such sale or transfer, future sales of the securities covered by the leak-out agreement entered into by the original owner (together with certain of its affiliate) and the purchaser or transferee will be aggregated to determine compliance with the terms of the leak-out agreement.

We, for a period of 30 days following the later of (i) the date that the Resale Registration Statement is declared effective by the SEC and (ii) the date that Shareholder Approval is obtained, and certain officers and directors of the Company, for a period of 90 days following the date the Resale Registration Statement is declared effective by the SEC, have agreed to be subject to a lock-up period, subject to certain exceptions. This means that, during the applicable lock-up period, we and such persons may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any of our depositary shares or any securities convertible into, or exercisable or exchangeable for, Depositary Shares, subject to customary exceptions. In addition, we have agreed to not issue any securities that are subject to a price reset based on the trading prices of our ordinary shares or upon a specified or contingent event in the future or enter into any agreement to issue securities at a future determined price for a period of one year following the closing date of the Private Placement, subject to an exception.

The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of Depositary Shares and warrants by the placement agent acting as principal. Under these rules and regulations, the placement agent:

may not engage in any stabilization activity in connection with our securities; and

may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.

From time to time, the placement agent may provide in the future various advisory, investment and commercial banking and other services to us in the ordinary course of business, for which they have received and may continue to receive customary fees and commissions. The placement agent has received compensation in connection with the December Registered Direct and February Private Placement.

Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.” The closing price of our Depositary Shares on May 22, 2023, as reported by the NASDAQ Stock Market LLC, was $0.19 per share.

S-45

Table of Contents

LEGAL MATTERS

Certain legal matters in connection with the securities offered hereby will passed upon for us by Orrick, Herrington & Sutcliffe LLP, New York, New York and Brown Rudnick LLP, London, United Kingdom. Ellenoff Grossman & Schole LLP, New York, New York, is counsel to the placement agent in connection with this offering.

EXPERTS

The financial statements as of December 31, 2022, and for the each of the three years in the period then ended, incorporated by reference into this prospectus supplement and in the Registration Statement have been so incorporated in reliance on a report of Mazars LLP, an independent registered accounting firm, given on authority of said firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2022 contains an explanatory paragraph regarding our ability to continue as a going concern.

Mazars LLP, London, United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

SERVICE OF PROCESS AND ENFORCEMENT OF JUDGMENTS

We are incorporated under the laws of England and Wales. All of our directors and officers are residents of jurisdictions outside the United States. Our corporate headquarters is located in the United Kingdom and all or a substantial portion of our assets, and all or a substantial portion of the assets of our directors and officers, are located outside of the United States. As a result, it may be difficult for you to serve legal process on us or our directors or have any of them appear in a U.S. court.

We have appointed Puglisi & Associates as our authorized agent upon whom process may be served in any action instituted in any U.S. federal or state court having subject matter jurisdiction arising out of or based upon the securities offered by this prospectus.

We understand that in England it may not be possible to bring proceedings or enforce a judgment of a U.S. court in respect of civil liabilities based solely on the federal securities laws of the United States. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in England. An award of damages is usually considered to be punitive if it does not seek to compensate the claimant for loss or damage suffered and is instead intended to punish the defendant. In addition to public policy aspects of enforcement, such as the aforementioned, the enforceability of any judgment in England will depend on the particular facts of the case and the relevant circumstances, for example (and expressly without limitation), whether there are any relevant insolvency proceedings which may affect the ability to enforce a judgment. In addition, the United States and the United Kingdom have not currently entered into a treaty (or convention) providing for the reciprocal recognition and enforcement of judgments (although both are contracting states to the New York Convention on the Recognition and Enforcement of Foreign Arbitral).

S-46

Table of Contents

PROSPECTUS

$25,000,000

MIDATECH PHARMA PLC

Ordinary Shares

American Depositary Shares representing Ordinary Shares

Warrants

Units

This prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering, up to $25,000,000 of any combination of the securities described in this prospectus, either individually or in units. We may also offer American Depositary Shares, or ADSs, representing ordinary shares upon the exercise of warrants.

This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus or any prospectus supplement, carefully before you invest.

Our securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For additional information on the methods of sale, you should refer to the section titled “Plan of Distribution” in this prospectus and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.

Our ADSs, each representing 25 ordinary shares, are listed on The Nasdaq Capital Market under the symbol “MTP.” The last reported closing price of ADSs on The Nasdaq Capital Market on October 17, 2022 was $1.9405.

Our ordinary shares are admitted for trading on AIM, a market operated by the London Stock Exchange plc, or AIM, under the listing code “MTPH.” The last reported closing price of our ordinary shares on AIM on October 17, 2022 was £0.0725.

The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The Nasdaq Capital Market, AIM or any securities market or other securities exchange of the securities covered by the prospectus supplement. Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable.

As of October 14, 2022, the aggregate market value of our outstanding ordinary shares held by non-affiliates, or public float, was approximately $13,547,724, based on 98,493,413 of our ordinary shares outstanding, of which approximately 87,972,237 shares are held by non-affiliates, and a per share price of approximately $0.154, which represents one-twenty fifth of $3.85, which was the price of our ADSs on September 12, 2022, and which was the highest reported closing sale price of our ADSs on The Nasdaq Capital Market, the principal market for our common equity, in the 60 days prior to October 14, 2022. We have not offered any securities pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that ends on and includes the date of this prospectus. Pursuant to General Instruction I.B.5. of Form F-3, in no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75 million.

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described on page 4 of this prospectus under the caption “Risk Factors.” We may also include specific risk factors in supplements to this prospectus under the caption “Risk Factors.” This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is October 26, 2022.

TABLE OF CONTENTS

	Page

ABOUT THIS PROSPECTUS	1
PRESENTATION OF FINANCIAL INFORMATION AND OTHER DATA	1
PROSPECTUS SUMMARY	2
RISK FACTORS	4
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS	5
CAPITALIZATION	7
USE OF PROCEEDS	8
PLAN OF DISTRIBUTION	9
DESCRIPTION OF SHARE CAPITAL	11
DESCRIPTION OF WARRANTS	26
DESCRIPTION OF UNITS	27
DESCRIPTION OF AMERICAN DEPOSITARY SHARES	28
EXPENSES	34
LEGAL MATTERS	35
EXPERTS	35
ENFORCEMENT OF JUDGMENTS	35
WHERE YOU CAN FIND MORE INFORMATION	35
INCORPORATION OF DOCUMENTS BY REFERENCE	36

Table of Contents

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may offer ADSs representing our ordinary shares, various series of warrants, and units, in one or more offerings, with a total value of up to $25,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering.

This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. The prospectus supplement may also add, update or change information contained or incorporated by reference in this prospectus. However, no prospectus supplement will offer a security that is not registered and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable prospectus supplements and the documents incorporated by reference into this prospectus, includes all material information relating to the offering of securities under this prospectus. You should carefully read this prospectus, the applicable prospectus supplement, the information and documents incorporated herein by reference and the additional information under the headings “Where You Can Find More Information” and “Incorporation of Documents by Reference” before making an investment decision.

You should rely only on the information we have provided or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any prospectus supplement is accurate only as of the date on the front of the document and that any information we have incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security.

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

This prospectus may not be used to consummate sales of our securities unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control.

Unless the context specifically indicates otherwise, references in this prospectus to “Midatech Pharma PLC,” “Midatech,” “the Company,” “we,” “our,” “ours,” “us,” “the Group,” or similar terms refer to Midatech Pharma PLC and its subsidiaries. In this prospectus, we sometimes refer to the Company’s ordinary shares, nominal value 0.1p per share, or the ordinary shares, the American Depositary Shares representing the ordinary shares, or the ADSs, warrants to acquire ordinary shares, or any units thereof.

PRESENTATION OF FINANCIAL INFORMATION AND OTHER DATA

We report under International Financial Reporting Standards as issued by the International Accounting Standards Board, or IFRS. None of the financial statements presented or incorporated by reference in this prospectus were prepared in accordance with generally accepted accounting principles in the United States. We present our financial statements in British pounds sterling and in accordance with IFRS. All references in this prospectus to “$” and “U.S. dollars” mean U.S. dollars and all references to “£”, “p” and “GBP” mean British pounds sterling (or a unit thereof), unless otherwise noted.

On September 26, 2022, we effected a change in the number of our ordinary shares represented by our ADSs, issued by The Bank of New York Mellon as depositary, from five of our ordinary shares per ADS to 25 ordinary shares per ADS. The change in ratio had the same effect as a one-for-5 reverse stock split of the ADSs, reducing the number of outstanding ADSs, as of the close of business on September 26, 2022, to approximately 3,940,000. Our ordinary shares, which were not affected by the change, continue to trade on AIM. The change in the number of ADSs resulting from the change in ratio has been applied retroactively to all share and per share amounts presented in this prospectus; provided, however, that such changes have not been made to the financial statements and accompanying notes incorporated herein by reference.

Table of Contents

PROSPECTUS SUMMARY

The following is a summary of what we believe to be the most important aspects of our business and the offering of our securities under this prospectus. We urge you to read this entire prospectus, including the more detailed consolidated financial statements, notes to the consolidated financial statements and other information incorporated by reference from our other filings with the SEC or included in any applicable prospectus supplement. Investing in our securities involves risks. Therefore, carefully consider the risk factors set forth in any prospectus supplements and in our most recent filings with the SEC including our Annual Reports on Form 20-F and reports on Form 6-K, as well as other information in this prospectus and any prospectus supplements and the documents incorporated by reference herein or therein, before purchasing our securities. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities.

About Midatech Pharma PLC

We are focused on the research and development of medicines which we believe would benefit from improved bio-delivery and/or bio-distribution using our using our proprietary platform drug delivery technologies:

Our Q-SpheraTM platform: Our disruptive polymer microsphere microtechnology is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months.

Our MidaSolveTM platform: Our innovative oligosaccharide nanotechnology is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

MidaCoreTM platform: Our leading-edge gold nanoparticle, or GNP, nanotechnology is used for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents.

Additional Information

For additional information related to our business and operations, please refer to the reports incorporated herein by reference, including the Annual Report on Form 20-F of Midatech Pharma PLC for the year ended December 31, 2021 and the Reports on Form 6-K furnished with the SEC, as described under the caption “Incorporation of Documents by Reference” on page 36 of this prospectus.

Our Corporate Information

We are a public limited company incorporated under the laws of England and Wales under registered number 09216368. Our principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our principal executive office is +44 29 2048 0180. Our service agent in the United States is located at Puglisi and Associates, 850 Library Avenue Newark, Delaware 19711. Our ordinary shares are admitted for trading on AIM under the listing code “MTPH.” Our ADSs, each representing 25 ordinary shares, are listed on The Nasdaq Capital Market under the symbol “MTP.” Our website is located at http://midatechpharma.com. We do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus.

Offerings Under This Prospectus

Under this prospectus, we may offer ordinary shares, ADSs representing our ordinary shares, and/or various series of warrants to purchase any of such securities, either individually or in units, with a total value of up to $25,000,000, from time to time at prices and on terms to be determined by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:

designation or classification;

aggregate principal amount or aggregate offering price;

maturity, if applicable;

rates and times of payment of interest or dividends, if any;

redemption, conversion or sinking fund terms, if any;

voting or other rights, if any; and

conversion or exercise prices, if any.

aggregate principal amount or aggregate offering price;

maturity, if applicable;

rates and times of payment of interest or dividends, if any;

redemption, conversion or sinking fund terms, if any;

voting or other rights, if any; and

conversion or exercise prices, if any.

Table of Contents

The prospectus supplement also may add, update or change information contained in this prospectus or in documents we have incorporated by reference into this prospectus. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.

We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we offer securities through agents or underwriters, we will include in the applicable prospectus supplement:

the names of those agents or underwriters;

applicable fees, discounts and commissions to be paid to them;

details regarding over-allotment options, if any; and

the net proceeds to us.

This prospectus may not be used to consummate a sale of any securities unless it is accompanied by a prospectus supplement.

Table of Contents

RISK FACTORS

Investing in our securities involves significant risk. The prospectus supplement applicable to each offering of our securities will contain a discussion of the risks applicable to an investment in the company. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading “Risk Factors” in the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading “Risk Factors” included in our most recent Annual Report on Form 20-F and any subsequent Annual Reports on Form 20-F we file after the date of this prospectus, and all other information contained in or incorporated by reference into this prospectus or the registration statement of which this prospectus forms a part, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the risk factors and other information contained in any applicable prospectus supplement before acquiring any of our securities. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus and the documents incorporated by reference in this prospectus include forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “targets,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus and incorporated by reference in this prospectus, we caution you that these statements are based on our projections of the future that are subject to known and unknown risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements, to differ. The sections in our periodic reports, including our Annual Report on Form 20-F for the fiscal year ended December 31, 2021, titled “Business Overview,” “Risk Factors,” and “Operating and Financial Review and Prospects,” as well as other sections in this prospectus and the documents or reports incorporated by reference in this prospectus, discuss some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements about:

our requirement for additional financing and our ability to continue as a going concern;

our estimates regarding losses, expenses, future revenues, and capital requirements;

our ability to successfully develop, test, and partner with a licensee to manufacture or commercialize products for conditions using our technology platforms;

the successful commercialization and manufacturing of any future product candidate we may commercialize or license;

the success and timing of preclinical studies and clinical trials, if any;

shifts in our business and commercial strategy;

the filing and timing of regulatory filings, including investigational new drug applications, with respect to any of our products and the receipt of any regulatory approvals;

the anticipated medical benefits of our products;

the difficulties in obtaining and maintaining regulatory approval of our product candidates, and the labeling under any approval we may obtain;

the success and timing of the potential commercial development of our product candidates and any product candidates we may acquire in the future, including MTX110;

our plans and ability to develop and commercialize our product candidates and any product candidates we may acquire in the future;

the ability to manufacture products in third-party facilities;

the rate and degree of market acceptance of any of our product candidates;

the successful development of our commercialization capabilities, including our internal sales and marketing capabilities;

obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;

the success of competing therapies and products that are or become available;

the success of any future strategic acquisitions;

cybersecurity and other cyber incidents;

industry trends;

the impact of government laws and regulations;

regulatory, economic and political developments in the United Kingdom, the European Union, the United States and other foreign countries, including any impact from the United Kingdom leaving the European Union;

the difficulties doing business internationally, including any risks related to the novel strain of coronavirus, COVID-19;

the ownership of our ordinary shares and ADSs;

our ability to meet the listing criteria required to remain listed on The Nasdaq Capital Market;

our status as a foreign private issuer;

our ability to recruit or retain key scientific or management personnel or to retain our senior management;

the impact and costs and expenses of any litigation we may be subject to now or in the future; and

the performance of third parties, including joint venture partners, our collaborators, third-party suppliers and parties to our licensing agreements.

Table of Contents

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important cautionary statements in this prospectus or in the documents incorporated by reference in this prospectus, particularly in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. For a summary of such factors, please refer to the section titled “Risk Factors” in this prospectus, as updated and supplemented by the discussion of risks and uncertainties under “Risk Factors” contained in any supplements to this prospectus and in our most recent Annual Report on Form 20-F, as revised or supplemented by our subsequent periodic reports filed under the Exchange Act, as well as any amendments thereto, as filed with the SEC and which are incorporated herein by reference. The information contained in this document is believed to be current as of the date of this document. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this prospectus or in any document incorporated herein by reference might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this prospectus or the date of the document incorporated by reference in this prospectus. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Table of Contents

CAPITALIZATION

Our capitalization will be set forth in a prospectus supplement to this prospectus or in a report on Form 6-K subsequently furnished to the SEC and specifically incorporated herein by reference.

Table of Contents

USE OF PROCEEDS

Unless otherwise indicated in the applicable prospectus supplement, we intend to use any net proceeds from the sale of securities under this prospectus for general corporate purposes, including development of our clinical and preclinical programs, other research and development costs, acquisitions of development or commercial assets, working capital and capital expenditures. We have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant to this prospectus for any purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade and interest-bearing securities.

Table of Contents

PLAN OF DISTRIBUTION

We may offer securities under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities (1) through underwriters or dealers, (2) through agents or (3) directly to one or more purchasers, or through a combination of such methods. We may distribute the securities from time to time in one or more transactions at:

a fixed price or prices, which may be changed from time to time;

market prices prevailing at the time of sale;

prices related to the prevailing market prices; or

negotiated prices.

We may directly solicit offers to purchase the securities being offered by this prospectus. We may also designate agents to solicit offers to purchase the securities from time to time, and may enter into arrangements for “at-the-market,” equity line or similar transactions. We will name in a prospectus supplement any underwriter or agent involved in the offer or sale of the securities.

If we utilize a dealer in the sale of the securities being offered by this prospectus, we will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.

If we utilize an underwriter in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter at the time of sale, and we will provide the name of any underwriter in the prospectus supplement which the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of the securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and the underwriter may compensate those dealers in the form of discounts, concessions or commissions.

With respect to underwritten public offerings, negotiated transactions and block trades, we will provide in the applicable prospectus supplement information regarding any compensation we pay to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof.

If so indicated in the applicable prospectus supplement, we will authorize underwriters, dealers or other persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in each applicable prospectus supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in each applicable prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any conditions except that:

the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of the jurisdiction to which that institution is subject; and

if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.

One or more firms, referred to as “remarketing firms,” may also offer or sell the securities, if a prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as our agents. These remarketing firms will offer or sell the securities in accordance with the terms of the securities. Each prospectus supplement will identify and describe any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm’s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms may be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary course of business.

Certain underwriters may use this prospectus and any accompanying prospectus supplement for offers and sales related to market-making transactions in the securities. These underwriters may act as principal or agent in these transactions, and the sales will be made at prices related to prevailing market prices at the time of sale. Any underwriters involved in the sale of the securities may qualify as “underwriters” within the meaning of Section 2(a)(11) of the Securities Act. In addition, the underwriters’ commissions, discounts or concessions may qualify as underwriters’ compensation under the Securities Act and the rules of the Financial Industry Regulatory Authority, Inc., or FINRA.

Table of Contents

ADSs representing our ordinary shares sold pursuant to the registration statement of which this prospectus is a part will be authorized for listing and trading on The Nasdaq Capital Market. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The Nasdaq Capital Market or any securities market or other securities exchange of the securities covered by the prospectus supplement. Underwriters may make a market in our ADSs, but will not be obligated to do so and may discontinue any market making at any time without notice. We can make no assurance as to the liquidity of or the existence, development or maintenance of trading markets for any of the securities.

In order to facilitate the offering of the securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than we sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing the applicable security in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if the securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time.

The underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course of their business.

Table of Contents

DESCRIPTION OF SHARE CAPITAL

The following describes our issued share capital, summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the United Kingdom and the United States. Please note that this summary is not intended to be exhaustive. For further information please refer to the full version of our articles of association, which is included as an exhibit to the registration statement of which this prospectus is part.

General

Issued Share Capital

Our issued share capital as of June 30, 2022 was 98,493,413 ordinary shares. Each ordinary share has a nominal value 0.1p per share. Each issued ordinary share is fully paid. We currently have 1,000,001 deferred shares and no preference shares in our issued share capital.

There is no limit to the number of ordinary shares or preference shares that we are authorized to issue, as the concept of authorized capital is no longer applicable under the provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to any ordinary shares.

We are not permitted under English law to hold our own ordinary shares unless they are repurchased by us and held in treasury. We do not currently hold any of our own ordinary shares.

History of Share Capital

Since January 1, 2019, our issued share capital has changed as provided below.

On February 26, 2019, we issued 10,389,610 units to new investors pursuant to a subscription agreement, or the subscription, for aggregate consideration of approximately £8.0 million. Each unit consisted of one ordinary share and one warrant to acquire ordinary shares.

On February 26, 2019, we issued (i) 4,331,384 units in connection with a placing, or the 2019 Placing, to certain new and existing investors and (ii) 1,716,952 ordinary shares to an existing investor, for an aggregate consideration of approximately £4.7 million. Each unit consisted of one ordinary share and one warrant to acquire ordinary shares.

On February 26, 2019, we issued 972,828 units in connection with an open offer to all of our existing shareholders who did not participate in the 2019 Placing, for an aggregate consideration of approximately £0.75 million. Each unit consisted of one ordinary share and one warrant to acquire ordinary shares.

On April 8, 2019, we effected a ratio change to our ADSs, pursuant to which the ratio of ordinary shares to ADSs was changed such that one ADS represented 20 ordinary shares. Our ordinary shares were not affected by this change.

On October 8, 2019, we issued 25,000 ordinary shares for purchase by the Midatech Pharma Share Incentive Plan.

On October 25, 2019, we sold to an institutional investor 3,000,000 ordinary shares represented by 120,000 ADSs in a registered direct offering at $25.00 per ADS, resulting in gross proceeds of $3.0 million. In addition, we issued to the investor unregistered warrants to purchase a total of 3,000,000 ordinary shares represented by 120,000 ADSs in a private placement, or the October Private Placement Warrants. We also issued unregistered placement agent warrants to purchase a total of 6,000 ordinary shares represented by 6,000 ADS to affiliates of H.C. Wainwright & Co., Inc. in a private placement, or the Wainwright October Warrants.

On March 3, 2020, following shareholder approval, we effected a one-for-20 reverse split of our ordinary shares and our ordinary shares began trading on AIM, on a split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock split. As a result of the reverse stock split, the number of issued and outstanding ordinary shares was reduced to 23,494,981 shares as of March 3, 2020.

Concurrently with the reverse split, on March 3, 2020 we effected a ratio change in the number of ordinary shares represented by our ADSs from 20 ordinary shares per ADS to five Ordinary Shares per ADS.

On May 20, 2020, we sold to certain institutional investors 9,090,910 ordinary shares represented by 363,636 ADSs in a registered direct offering at $8.25 per ADS, resulting in gross proceeds of $3.0 million. In addition, we issued to the investors unregistered warrants to purchase a total of 9,090,910 ordinary shares represented by 363,636 ADSs in a private placement, or the May Private Placement Warrants. We also issued unregistered placement agent warrants to purchase a total of 454,546 ordinary shares represented by 18,182 ADSs to affiliates of H.C. Wainwright & Co., Inc. in a private placement, or the Wainwright May Warrants.

On May 22, 2020, we issued 6,666,666 units, or Units, to certain non-U.S. investors in a placing in the United Kingdom for aggregate gross proceeds of £1.8 million. Each Unit comprised one new ordinary share and one warrant to purchase ordinary shares, or the UK Warrants. We also issued unregistered placement agent warrants to purchase a total of 333,333 ordinary shares to Turner Pope Investments (TPI) Limited, or Turner Pope.

Table of Contents

On July 27, 2020, we issued 21,296,295 ordinary shares, including 2,777,777 ordinary shares issued pursuant to a broker option, to certain non-U.S. investors in a placing in the United Kingdom for aggregate gross proceeds of £5.75 million.

On August 19, 2020, we issued 2,500,000 ordinary shares represented by 100,000 ADSs upon the exercise of warrants issued in May 2020 at an exercise price of $10.25 per share.

On September 30, 2020, we issued 25,000 ordinary shares to be purchased under the Midatech Pharma Share Incentive Plan.

On February 19, 2021, we issued 306,815 ordinary shares represented by 12,273 ADSs upon the exercise of warrants issued in May 2020 at an exercise price of $10.3125 per share.

On July 6, 2021, we issued 35,087,720 ordinary shares to certain non-U.S. investors in a placing in the United Kingdom for aggregate gross proceeds of £10.0 million.

On March 22, 2022, we issued 26 ordinary shares upon the exercise of 26 warrants issued in February 2019 at an exercise price of £10 per share.

On May 3, 2022, we issued 25,000 ordinary shares to be purchased under the Midatech Pharma Share Incentive Plan.

On August 3, 2022, we issued warrants to purchase 333,333 ordinary shares at an exercise price of £0.135 per share.

On September 26, 2022, we effected a ratio change to our ADSs, pursuant to which the ratio of ordinary shares to ADSs was changed such that one ADS represented 25 ordinary shares. Our ordinary shares were not affected by this change.

Options

We have established the Midatech Pharma PLC 2014 Enterprise Management Incentive Scheme pursuant to which we have issued options to purchase ordinary shares to employees and directors. As of June 30, 2022, there were options to purchase 2,945,000 ordinary shares. The options lapse after ten years from the date of the grant. As of June 30, 2022, the weighted average remaining life of the options was 8.7 years.

In addition, we maintain the Midatech Pharma PLC 2016 U.S. Option Plan, pursuant to which we have issued options to purchase ordinary shares to employees in the United States. With the sale of Midatech Pharma US Inc., options granted to employees remaining with the business at the time of sale were deemed to be fully vested and such employees were granted two years in which to exercise. At the time of such sale, there were approximately 505,000 options subject to this. Following the sale of Midatech Pharma US Inc., no further options have since been, nor will be, granted under such plan.

In connection with our acquisition of DARA BioSciences, Inc., or DARA, in December 2015, we assumed all of DARA’s outstanding options, or DARA Options. As of June 30, 2022, there were outstanding DARA Options to purchase 2,822 ordinary shares with a weighted average remaining life of 2.4 years. All ordinary shares delivered to holders of DARA Options will be delivered in the appropriate amount of ADSs.

Warrants

DARA Warrants

In connection with our acquisition of DARA, we assumed all of DARA’s existing warrants. As of June 30, 2022, there were DARA warrants outstanding exercisable for 4,080 ordinary shares, with a weighted average exercise price of $61.03. All ordinary shares delivered to holders of such DARA warrants will be delivered in the appropriate amount of ADSs.

October 2019 and May 2020 Warrants

Exercisability. The October Private Placement Warrants and Wainwright October Warrants became exercisable on December 23, 2019. The May Private Placement Warrants and Wainwright May Warrants became exercisable upon issuance. The October Private Placement Warrants and May Private Placement Warrants will expire five and one-half years from the initial exercise date, and the Wainwright October Warrants and Wainwright May Warrants will expire on October 22, 2024 and May 18, 2025, respectively. The holder shall deliver the aggregate exercise price for the ADSs specified in the exercise notice within two trading days following the date of exercise (subject to the ‘cashless exercise’ arrangements described below).

Table of Contents

Cashless Exercise. With respect to the October Private Placement Warrants and Wainwright October Warrants, if, more than six months after the date of issuance of such warrants, there is no effective registration statement registering, or no current prospectus available for, the resale of the Depositary Shares underlying such warrants, the holder may exercise the warrant, in whole or in part, on a cashless basis. With respect to the May Private Placement Warrants and Wainwright May Warrants, if there is no effective registration statement registering, or no current prospectus available for, the resale of the ADSs s underlying such warrants, the holder may exercise the warrant, in whole or in part, on a cashless basis.

Exercise Price. The exercise price of (i) each October Private Placement Warrant and Wainwright October Warrant is $31.25 per ADSs and (ii) each May Private Placement Warrants and Wainwright May Warrant is $10.25 and $10.3125 per ADSs, respectively, each subject to the ‘cashless exercise’ arrangements described above and to adjustment as described below.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder or any such affiliate, would beneficially own in excess of, at the initial option of the holder thereof, 4.99% or 9.99%, as applicable, of the number of ordinary shares outstanding immediately after giving effect to the issuance of the ordinary shares underlying the ADSs upon such exercise. The holder of the warrant, upon notice to us, may increase or decrease the beneficial ownership limitation to a percentage not to exceed 9.99%, provided that any increase in the beneficial ownership limitation shall not be effective until 61 days following notice to us. Beneficial ownership of the holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange Act, and the rules and regulations promulgated thereunder.

Stock dividends and stock splits. If we pay a stock dividend or otherwise make a distribution payable in ADSs or ordinary shares, or any other equity or equivalent securities, subdivide or combine outstanding ADSs or ordinary shares s, or reclassify ADSs, ordinary shares or any shares of our capital stock, the exercise price of each warrant will be adjusted by multiplying the then exercise price by a fraction, the numerator of which shall be the number of ADSs (excluding treasury shares, if any) outstanding immediately before such event, and the denominator of which shall be the number of ADSs outstanding immediately after such event.

Rights Offerings; pro rata distributions. If we issue ordinary share equivalents or rights to purchase shares, warrants, securities or other property pro rata to holders of ADSs, a holder of a warrant will be entitled to acquire, subject to the beneficial ownership limitation described above, such securities or property that such holder could have acquired if such holder had held the number of ADSs issuable upon complete exercise of the warrant immediately prior to the date a record is taken for such issuance. If we declare or make any dividend or other distribution of assets or rights to acquire assets to holders of ADSs or ordinary shares, a holder of a warrant will be entitled to participate, subject to the beneficial ownership limitation, in such distribution to the same extent that the holder would have participated therein if the holder had held the number of ADSs issuable upon full exercise of the warrant.

May 2020 United Kingdom Placing Warrants

On May 22, 2020, we issued 6,666,666 Units, with each Unit comprising one new ordinary shares and one UK Warrant. The exercise price of the UK Warrants is £0.34 per share and it expires five years and six months from the issuance date. We also issued UK Warrants to purchase a total of 333,333 Ordinary Shares to Turner Pope, the placing agent, in connection with the closing of such offering, on the same terms and conditions as the other investors in the offering.

August 2022 Warrants

On August 3, 2022, we issued warrants to purchase 333,333 ordinary shares to Strand Hanson Limited, in payment for services rendered. The exercise price of such warrants is £0.135 per share and it expires three years from the issuance date.

Articles of Association

The following is a summary of certain provisions of our articles of association. Please note that this is only a summary and is not intended to be exhaustive. For further information please refer to the full version of our articles of association, which is included as an exhibit to our most recent Annual Report on Form 20-F.

Table of Contents

Shares and Rights Attaching to Them

Objects

The objects of our Company are unrestricted.

Share Rights

Voting Rights

Without prejudice to any rights or restrictions as to voting rights attached to any shares forming part of our share capital from time to time, the voting rights attaching to shares are as follows:

on a show of hands every shareholder who is present in person and each duly authorized representative present in person of a shareholder that is a corporation shall have one vote;

on a poll every shareholder who is present in person or by proxy shall have one vote for each share of which he is the holder.

At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is demanded. Subject to the provisions of the Companies Act, as described in “Differences in Corporate Law - Voting Rights” in this prospectus, a poll may be demanded by:

the chairman of the meeting;

at least five shareholders present in person or by proxy and entitled to vote;

any shareholder(s) present in person or by proxy and representing in the aggregate not less than 10% of the total voting rights of all shareholders having the right to vote on the resolution; or

Restrictions on Voting

A shareholder’s right to attend general or class meetings of the Company or to vote in respect of his shares may be suspended by the Board of Directors in accordance with our Articles of Association if he fails to comply with a proper request for the disclosure of interests regarding the shares. See “Other United Kingdom Law Considerations—Disclosure of Interest in Shares” in this prospectus.

Dividends

Table of Contents

A shareholder’s right to receive dividends on his shares may, if they represent more than 0.25% of the issued shares of that class, be suspended by the directors if he fails to comply with a proper request for the disclosure of interests regarding the shares. See “Other United Kingdom Law Considerations—Disclosure of Interests in Shares” in this prospectus.

Change of Control

There is no specific provision in our Articles of Association that would have the effect of delaying, deferring or preventing a change of control. We are, however, subject to the provisions of the United Kingdom City Code on Takeovers and Mergers, or the City Code, which contains detailed provisions regulating the timing and manner of any takeover offer for those of the Company’s shares which confer voting rights. See “Other United Kingdom Law Considerations—City Code on Takeovers and Mergers” in this prospectus.

Variation of Rights

Alteration of Share Capital and Repurchases

Subject to the provisions of the Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time:

increase our share capital by allotting and issuing new shares in accordance with the our articles of association and any relevant shareholder resolution;

consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than the existing shares;

subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than our existing shares; or

redenominate our share capital or any class of share capital.

Preemptive Rights and New Issuance of Shares

By way of resolutions passed at our annual general meeting held on June 20, 2022, authorities were given to the directors to allot shares in the Company, or to grant rights to subscribe for or to convert or exchange any security into shares in the Company, up to an aggregate nominal amount representing one-third of our issued share capital for a period up to the earlier of the conclusion of our 2023 annual general meeting or 15 months from the date of passing of the first resolutions at the annual general meeting for 2023 referenced above. Pre-emptive rights under the Companies Act will not apply in respect of allotment of shares for cash made pursuant to such authority, up to approximately 10% of the issued share capital. Renewal of such authorization is expected to be sought at each of our annual general meetings.

In circumstances where we allot further ordinary shares, we must apply for such new ordinary shares to be admitted to trading on AIM, which in some instances requires the publication of an admission document.

Transfer of Shares

Table of Contents

The Board of Directors may decline to register any transfer of any share unless it is:

a fully paid share;

a share on which the Company has no lien;

in respect of only one class of shares;

in favor of a single transferee or not more than four transferees;

duly stamped or duly certificated or otherwise shown the satisfaction of the Board of Directors to be exempt from any required stamp duty; or

delivered for registration at the Company’s registered office or such other place as the Board of Directors may decide, accompanied by the certificate for the shares to which it relates (other than uncertificated shares) and any other evidence the Board of Directors may reasonably require to provide the title to such share of the transferor.

CREST

To be traded on AIM, securities must be able to be transferred and settled through the CREST system. CREST is a computerized paperless share transfer and settlement system which allows securities to be transferred by electronic means, without the need for a written instrument of transfer. The Articles of Association are consistent with CREST membership and, among other things, allow for the holding and transfer of shares in uncertificated form.

Shareholder Meetings

Annual General Meetings

In accordance with the Companies Act, we are required in each year to hold an annual general meeting in addition to any other general meetings in that year and to specify the meeting as such in the notice convening it. The annual general meeting shall be convened whenever and wherever the board sees fit, subject to the requirements of the Companies Act, as described in “Differences in Corporate Law—Annual General Meeting” and “Differences in Corporate Law—Notice of General Meetings” in this prospectus.

Notice of General Meetings

The arrangements for the calling of general meetings are described in “Differences in Corporate Law—Notice of General Meetings” in this prospectus.

Subject to certain conditions, holders of ADSs are entitled to receive notices under the terms of the deposit agreement relating to the ADSs. See “Description of American Depositary Shares—Voting Rights” in this prospectus.

Quorum of General Meetings

Class Meetings

The provisions in the Articles of Association relating to general meetings apply to every separate general meeting of the holders of a class of shares except that:

no member, other than a member of the Board of Directors, shall be entitled to notice of it or attend such meeting unless he is a holder of shares of that class;

the quorum for such class meeting shall be two holders in person or by proxy representing not less than one-third in nominal value of the issued shares of the class;

at the class meeting, a holder of shares of the class present in person or by proxy may demand a poll and shall on a poll be entitled to one vote for every shares of the class held by him; and

if at any adjourned meeting of such holders a quorum is not present at the meeting, one holder of shares of the class present in person or by proxy at an adjourned meeting constitutes a quorum.

Table of Contents

Directors

Number of Directors

Appointment of Directors

Rotation of Directors

A director who retires at the annual general meeting shall be eligible for re-election.

Director’s Interests

may be a party to, or otherwise interested in, any transaction or arrangement with us or in which we are otherwise interested;

Table of Contents

the resolution relates in any way to the purchase or maintenance for the directors of insurance; or

the resolution is in respect of any matter in which the interest of the director cannot reasonably be regarded as conflicting.

A director shall not be counted in the quorum present at a meeting in relation to a resolution on which he is not entitled to vote.

An interest of a person connected with a director shall be treated as an interest of the director and Section 252 of the Companies Act shall determine whether a person is connected with a director.

Directors’ Fees and Remuneration

Each of the directors shall be paid a fee at such rate as may from time to time be determined by the Board of Directors (or for the avoidance of doubt any duly authorized committee of the Board of Directors) provided that the aggregate of all such fees so paid to directors shall not exceed £300,000 per annum, or such higher amount as may from time to time be determined by ordinary resolution of shareholders.

An executive director shall receive such remuneration as the Board of Directors may determine, and either in addition to or in lieu of his remuneration as a director as detailed above.

Age Limitations and Share Ownership

We do not have any age limitations for our directors, nor do we have mandatory retirement as a result of reaching a certain age. Our directors are not required to hold any shares in the Company.

Borrowing Power

Liability of Midatech and its Directors and Officers

Table of Contents

Under a deed poll declared by us on August 5, 2015, or a Deed of Indemnity, our Board of Directors and our Company Secretary are indemnified against costs and liabilities incurred in connection with their office, other than any liability owed by such person to the Company itself (or any of our associated entities) and other than indemnification for liabilities in certain circumstances, which are prohibited by virtue of the Companies Act. The Deed of Indemnity provides that a director may also be lent sums to finance any relevant defense costs, provided that, in the event such proceedings involve criminal or civil matters in which the person is convicted or has a judgment made against him or her, then such loan must be repaid. Our total aggregate liability of Midatech under the Deed of Indemnity is £5 million.

Other United Kingdom Law Considerations

Notification of Voting Rights

A shareholder in a public company incorporated in the United Kingdom whose shares are admitted to trading on AIM is required pursuant to Rule 5 of the Disclosure Guidance and Transparency Rules of the United Kingdom Financial Conduct Authority to notify us of the percentage of his voting rights if the percentage of voting rights which he holds as a shareholder or through his direct or indirect holding of financial instruments (or a combination of such holdings) reaches, exceeds or falls below 3%, 4%, 5%, and each 1% threshold thereafter up to 100% as a result of an acquisition or disposal of shares.

Mandatory Purchases and Acquisitions

Sell Out

Disclosure of Interest in Shares

Table of Contents

Purchase of Own Shares

specify the maximum number of shares authorized to be acquired;

determine the maximum and minimum prices that may be paid for the shares; and

specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire.

We currently have authority from a resolution passed at our 2019 annual general meeting to purchase a maximum of 40,939,961 shares representing approximately 10% of our issued capital valid for a period up to the earlier of the conclusion of our 2020 annual general meeting or 15 months from the date of passing such resolution, although we do not currently have any distributable profits out of which such a purchase or redemption of shares may be made.

Distributions and Dividends

if, and to the extent that, the distribution itself, at the time that it is made, does not reduce the amount of the net assets to less than that total.

City Code on Takeovers and Mergers

As a United Kingdom incorporated public company with our registered office in the United Kingdom which is admitted to AIM, we are subject to the City Code, which is issued and administered by the United Kingdom Panel on Takeovers and Mergers, or the Panel. The City Code provides a framework within which takeovers of companies subject to it are conducted. In particular, the City Code contains certain rules in respect of mandatory offers. Under Rule 9 of the City Code, if a person:

acquires an interest in our shares which, when taken together with shares in which he or persons acting in concert with him are interested, carries 30% or more of the voting rights of our shares; or

who, together with persons acting in concert with him, is interested in shares that in the aggregate carry not less than 30% and not more than 50% of the voting rights in us, acquires additional interests in shares that increase the percentage of shares carrying voting rights in which that person is interested, the acquirer, and depending on the circumstances, its concert parties would be required (except with the consent of the Panel) to make a cash offer for our outstanding shares at a price not less than the highest price paid for any interests in the shares by the acquirer or its concert parties during the previous 12 months.

Table of Contents

Exchange Controls

There are no governmental laws, decrees, regulations or other legislation in the United Kingdom that may affect the import or export of capital, including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends, interest, or other payments by us to non-resident holders of our ordinary shares or ADSs, other than withholding tax requirements. There is no limitation imposed by English law or in the Articles of Association on the right of non-residents to hold or vote shares.

Differences in Corporate Law

The applicable provisions of the Companies Act differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act applicable to us and the Delaware General Corporation Law relating to shareholders’ rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and English law.

	England and Wales	Delaware
Number of Directors	Under the Companies Act, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company’s articles of association.	Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.

Removal of Directors	Under the Companies Act, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has with the company, provided 28 clear days’ notice of the resolution has been given to the company and its shareholders. On receipt of notice of an intended resolution to remove a director, the company must forthwith send a copy of the notice to the director concerned. Certain other procedural requirements under the Companies Act must also be followed such as allowing the director to make representations against his or her removal either at the meeting or in writing.	Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (a) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, shareholders may effect such removal only for cause, or (b) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.

Vacancies on the Board of Directors	Under English law, the procedure by which directors (other than a company’s initial directors) are appointed is generally set out in a company’s articles of association, provided that where two or more persons are appointed as directors of a public limited company by a single resolution of the shareholders such resolution must not be put to shareholders unless a resolution that it should be so made has first been agreed to by the shareholders without any vote being against it.	Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (a) otherwise provided in the certificate of incorporation or by-laws of the corporation or (b) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.

Annual General Meeting	Under the Companies Act, a public limited company must hold an annual general meeting in each six-month period beginning with the day following the company’s annual accounting reference date.	Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.

General Meeting	Under the Companies Act, a general meeting of the shareholders of a public limited company may be called by the directors. Shareholders holding at least 5% of the paid-up capital of the company carrying voting rights at general meetings can require the directors to call a general meeting and, if the directors fail to do so within a prescribed period, may themselves, or any of them representing more than one half of the total voting rights of all of them, call a general meeting.	Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.

Table of Contents

Notice of General Meetings	Under the Companies Act, 21 clear days’ notice must be given for an annual general meeting and any resolutions to be proposed at the meeting. Subject to a company’s articles of association providing for a longer period, at least 14 clear days’ notice is required for any other general meeting of a public limited company which fulfil certain conditions. In addition, certain matters, such as resolutions to remove directors or auditors, require special notice, which is 28 clear days’ notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders’ consent required being 100% of those entitled to attend and vote in the case of an annual general meeting and, in the case of any other general meeting, a majority in number of the shareholders having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to attend and vote at the meeting.	Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.

Quorum	Subject to the provisions of a company’s articles of association, the Companies Act provides that two shareholders present at a meeting (in person, by proxy or authorized under the Companies Act) shall constitute a quorum for companies with more than one shareholder.	The certificate of incorporation or bylaws may specify the number of shares, the holders of which shall be present or represented by proxy at any meeting in order to constitute a quorum, but in no event shall a quorum consist of less than one third of the shares entitled to vote at the meeting. In the absence of such specification in the certificate of incorporation or bylaws, a majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at a meeting of stockholders.

Proxy	Under the Companies Act, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the meeting on their behalf by proxy.	Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director’s voting rights as a director.

Pre-emptive Rights	Under the Companies Act, “equity securities”, being (i) shares in the company other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution (“ordinary shares”) or (ii) rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing equity shareholders in the company in proportion to the respective nominal value of their holdings, unless the period during which any such offer may be accepted as expired or the company has received notice of acceptance of refusal, or an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise (in each case in accordance with the provisions of the Companies Act).	Under Delaware law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.

Table of Contents

Authority to Allot	Under the Companies Act, the directors of a company must not allot shares or grant rights to subscribe for or to convert any security into shares unless an exception applies or an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise (in each case in accordance with the provisions of the Companies Act).	Under Delaware law, if the corporation’s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.

Liability of Directors and Officers	Under the Companies Act, any provision (whether contained in a company’s articles of association or any contract or otherwise) that purports to exempt a director of a company, to any extent, from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void. Any provision by which a company directly or indirectly provides an indemnity, to any extent, for a director of the company or of an associated company against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a director is also void except as permitted by the Companies Act, which provides exceptions for the company to (a) purchase and maintain insurance against such liability; (b) provide a “qualifying third party indemnity” (being an indemnity against liability incurred by the director to a person other than the company or an associated company); and (c) provide a “qualifying pension scheme indemnity” (being an indemnity against liability incurred in connection with the company’s activities as trustee of an occupational pension plan).	Under Delaware law, a corporation’s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for: • any breach of the director’s duty of loyalty to the corporation or its stockholders; • acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; • intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or • any transaction from which the director derives an improper personal benefit.

Voting Rights	Under the model articles of public companies, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or by the company’s articles of association, shareholders shall vote on all resolutions on a show of hands. Under the Companies Act, a poll may be demanded by (a) not fewer than five shareholders having the right to vote on the resolution; (b) any shareholder(s) representing not less than 10% of the total voting rights of all the shareholders having the right to vote on the resolution; or (c) any shareholder(s) holding shares in the company conferring a right to vote on the resolution being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right. A company’s articles of association may provide more extensive rights for shareholders to call a poll. Under English law, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in person or by proxy, who, being entitled to vote, vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present, in person or by proxy, at the meeting.	Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.

Table of Contents

Shareholder Vote on
Certain Transactions

The Companies Act provides for schemes of arrangement, which are arrangements or compromises between a company and any class of shareholders or creditors that are used in certain types of reconstructions, amalgamations, capital reorganizations or takeovers. These arrangements require:

• the approval at a shareholders’ or creditors’ meeting convened by order of the court, of a majority in number of shareholders or creditors representing 75% in value of the capital held by, or a class thereof, the class of shareholders or creditors, or class thereof present and voting, either in person or by proxy; and

• the approval of the court.

Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation’s assets or dissolution requires:

• the approval of the board of directors; and

• approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.

Standard of Conduct
for Directors

Under English law, a director owes various statutory and fiduciary duties to the company, including:

• to act in the way he considers, in good faith, would be most likely to promote the success of the company for the benefit of its shareholders as a whole, subject in certain specified circumstances to consider or act in the interests of the creditors of the company;

• to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the company;

• to act in accordance with the company’s constitution and only exercise his powers for the purposes for which they are conferred;

• to exercise independent judgement;

• to exercise reasonable care, skill and diligence;

• not to accept benefits from a third party conferred by reason of his being a director or doing, or not doing, anything as a director; and

• a duty to declare any interest that he has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the company.

Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.

Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.

In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.

Table of Contents

Shareholder
Litigation

Under English law, generally, the company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the company or where there is an irregularity in the company’s internal management. Notwithstanding this general position, the Companies Act provides that (i) a court may allow a shareholder to bring a derivative claim (that is, an action in respect of and on behalf of the company) in respect of a cause of action arising from an act or omission involving a director’s negligence, default, breach of duty or breach of trust and (ii) a shareholder may bring a claim for a court order where the company’s affairs have been or are being conducted in a manner that is unfairly prejudicial to some or all of its shareholders.

Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:

• state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and

• allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff’s failure to obtain the action; or

• State the reasons for not making the effort.

Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.

Listing

The ADSs are listed on The Nasdaq Capital Market under the symbol “MTP”.

Transfer Agent and Registrar

Our share register is maintained by our registrar, Neville Registrars Limited. The transfer agent and registrar for our ADSs is Computershare.

Table of Contents

DESCRIPTION OF WARRANTS

General

We may issue warrants to purchase our ordinary shares represented by ADSs in one or more series together with other securities or separately, as described in the applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants that we may offer. Particular terms of the warrants will be described in the warrant agreements and the prospectus supplement relating to the warrants.

The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:

the specific designation and aggregate number of, and the price at which we will issue, the warrants;

the currency or currency units in which the offering price, if any, and the exercise price payable;

the designation, amount and terms of the securities purchasable upon exercise of the warrants;

if applicable, the exercise price for our ADSs and the number of ADSs to be received upon exercise;

the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants;

whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit;

any applicable material U.S. federal income tax consequences and any applicable material U.K. tax consequences;

the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents;

the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange;

if applicable, the date from and after which the warrants and the ADSs will be separately transferable;

if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;

information with respect to book-entry procedures, if any;

the anti-dilution provisions of the warrants, if any;

any redemption or call provisions, if any;

whether the warrants may be sold separately or with other securities as parts of units; and

any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.

Transfer Agent and Registrar

The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.

Table of Contents

DESCRIPTION OF UNITS

The following description, together with the additional information that we include in any applicable prospectus supplements summarizes the material terms and provisions of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below.

We will incorporate by reference from reports that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we may offer under this prospectus, as well as any related free writing prospectuses and the complete unit agreement and any supplemental agreements that contain the terms of the units.

General

We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each security included in the unit. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.

We will describe in the applicable prospectus supplement the terms of the series of units being offered, including:

the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;

any provisions of the governing unit agreement that differ from those described below; and

any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.

The provisions described in this section, as well as those set forth in any prospectus supplement or as described under “Description of Share Capital,” “Description of American Depositary Shares,” and “Description of Warrants,” will apply to each unit, as applicable, and to any ordinary shares represented by ADSs or warrant included in each unit, as applicable.

Unit Agent

The name and address of the unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement.

Issuance in Series

We may issue units in such amounts and in such numerous distinct series as we determine.

Enforceability of Rights by Holders of Units

Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as a unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.

Table of Contents

DESCRIPTION OF AMERICAN DEPOSITARY SHARES

General

Our ADSs are deposited pursuant to the Amended and Restated Deposit Agreement dated February 8, 2021, among the Company, The Bank of New York Mellon as depositary, ands owners and holders of ADSs. The depositary registers and delivers the ADSs. Each ADS represents five ordinary shares (or a right to receive five ordinary shares) deposited with The Bank of New York Mellon, London Branch, or any successor, as custodian for the depositary. Each ADS also represents any other securities, cash or other property that may be held by the depositary. The deposited ordinary shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary’s office at which the ADSs are administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.

You may hold ADSs either (1) directly (a) by having an American Depositary Receipt, or ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (b) by having ADSs registered in your name in the Direct Registration System, or (2) indirectly by holding a security entitlement in ADSs through your broker or other financial institution. If you hold ADSs directly, you are a registered ADS holder. This description assumes you are a ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.

The Direct Registration System, or DRS, is a system administered by The Depository Trust Company, or DTC, pursuant to which the depositary may register the ownership of uncertificated ADSs, which ownership is confirmed by periodic statements sent by the depositary to the registered holders of uncertificated ADSs.

ADS holders are not treated as shareholders and do not have shareholder rights. English law governs shareholder rights. The depositary is the holder of the ordinary shares underlying the ADSs. As a holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary and you, as a ADS holder, and all other persons directly and indirectly holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. A copy of the deposit agreement is incorporated by reference as an exhibit to our most recent Annual Report on Form 20-F. New York law governs the deposit agreement and the ADSs.

The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADS.

Dividends and Other Distributions

How will you receive dividends and other distributions on the ordinary shares?

The depositary has agreed to pay you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, after deducting its fees and expenses. As a ADS holder, you will receive these distributions in proportion to the number of ordinary shares your ADSs represent.

Cash. We do not expect to declare or pay any cash dividends or cash distributions on our ADSs for the foreseeable future. The depositary will convert any cash dividend or other cash distribution we pay on the ADSs or any net proceeds from the sale of any ordinary shares, rights, securities or other entitlements into U.S. dollars if it can do so on a reasonable basis and at the then prevailing market rate, and can transfer the U.S. dollars to the United States. If that is not possible and lawful or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. Before making a distribution, any taxes or other governmental charges, together with fees and expenses of the depositary that must be paid, will be deducted. See the section titled “Item 10 E. Additional Information—Taxation” in our most recent Annual Report on Form 20-F for a summary of certain tax consequences in respect of dividends or distributions to holders of ADSs. It will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.

Ordinary Shares. The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution to the extent reasonably practicable and permissible under law. The depositary will only distribute whole ADSs. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new ordinary shares. The depositary may sell a portion of the distributed ordinary shares sufficient to pay its fees and expenses in connection with that distribution.

Elective Distributions in Cash or Shares. If we offer holders of our ordinary shares the option to receive dividends in either cash or shares, the depositary, after consultation with us, may make such elective distribution available to you as a holder of the ADSs. We must first instruct the depositary to make such elective distribution available to you. As a condition of making a distribution election available to ADS holders, the depositary may require satisfactory assurances from us that doing so would not require registration of any securities under the Securities Act. There can be no assurance that you will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of ordinary shares, or at all.

Table of Contents

Rights to Purchase Additional Ordinary Shares. If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the depositary may make these rights available to ADS holders. If the depositary decides it is not legal and practical to make the rights available but that it is practical to sell the rights, the depositary will use reasonable efforts to sell the rights and distribute the proceeds in the same way as it does with cash distributions. The depositary will allow rights that are not distributed or sold to lapse. In that case, you will receive no value for them.

If the depositary makes rights available to you, it will exercise the rights and purchase the ordinary shares on your behalf and in accordance with your instructions. The depositary will then deposit the ordinary shares and deliver ADSs to you. It will only exercise rights if you pay it the exercise price and any other charges the rights require you to pay and comply with other applicable instructions.

U.S. securities laws may restrict transfers and cancellation of the ADSs representing ordinary shares purchased upon exercise of rights. For example, you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted ADSs that have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions in place.

Other Distributions. The depositary will send to you anything else we distribute to holders of deposited securities by any means it determines is equitable and practicable. If it cannot make the distribution proportionally among the owners, the depositary may adopt another equitable and practical method. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property.

However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. In addition, the depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution.

Neither we nor the depositary are responsible for any failure to determine that it may be lawful or feasible to make a distribution available to any ADS holders. We have no obligation to register ADSs, ordinary shares, rights or other securities under the Securities Act. This means that you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.

Deposit, Withdrawal and Cancellation

How are ADSs issued?

The depositary will deliver ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, and delivery of any required endorsements, certifications or other instruments of transfer required by the depositary, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.

How can ADS holders withdraw the deposited securities?

You may surrender your ADSs at the depositary’s corporate trust office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, the depositary will transfer and deliver the ordinary shares and any other deposited securities underlying the ADSs to you or a person designated by you at the office of the custodian or through a book-entry delivery. Alternatively, at your request, risk and expense, the depositary will transfer and deliver the deposited securities at its corporate trust office, if feasible.

How do ADS holders interchange between certificated ADSs and uncertificated ADSs?

You may surrender your ADRs to the depositary for the purpose of exchanging your ADRs for uncertificated ADSs. The depositary will cancel the ADRs and will send you a statement confirming that you are the owner of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to you an ADR evidencing those ADSs.

Voting Rights

How do you vote?

You may instruct the depositary to vote the number of whole deposited ordinary shares your ADSs represent. The depositary will notify you of shareholders’ meetings or other solicitations of consents and arrange to deliver our voting materials to you if we ask it to. Those materials will describe the matters to be voted on and explain how you may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary.

The depositary will try, as far as practical, and subject to the laws of England and Wales and our Articles of Association, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders.

Table of Contents

The depositary will only vote or attempt to vote as you instruct or as described above. If we ask the depositary to solicit the ADS holders’ instructions to vote and a ADS holder fails to instruct the depositary as to the manner in which to vote by the specified date, such ADS holder will be deemed to have given a discretionary proxy to a person designated by us to vote the number of deposited securities represented by its ADSs, unless we notify the depositary that we do not wish to receive a discretionary proxy, there is substantial shareholder opposition to the particular question, or the particular question would have an adverse impact on our shareholders.

We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions provided that any such failure is in good faith. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted as you requested.

Except as described above, you will not be able to exercise your right to vote unless you withdraw the ordinary shares. However, you may not know about the shareholder meeting far enough in advance to withdraw the ordinary shares.

Fees and Expenses

What fees and expenses will you be responsible for paying?

Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees:

Persons depositing or withdrawing our ordinary shares or ADS holders must pay:		*For:*
5.00 USD (or less) per 100 ADSs (or portion of 100 ADSs)		Issue of ADSs, including issues resulting from a distribution of our ordinary shares or rights or other property

		Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates

0.05 USD (or less) per ADS		Any cash distribution to ADS holders

A fee equivalent to the fee that would be payable if securities distributed to ADS holders had been our ordinary shares and the ADSs had been deposited for issuance of ADSs		Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders

0.05 USD (or less) per ADS per calendar year		Depositary services

Registration or transfer fees		Transfer and registration of shares of our ordinary shares on our share register to or from the name of the depositary or its agent when persons deposit or withdraw our ordinary shares

Expenses of the Depositary		Cable and facsimile transmissions (when expressly provided in the deposit agreement)

		Converting foreign currency to U.S. dollars

Taxes and other governmental charges the depositary or the custodian has to pay on any ADS or our ordinary shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes		As necessary

Any charges incurred by the depositary or its agents for servicing the deposited securities		As necessary

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing our ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

Table of Contents

The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.

The depositary has agreed to reimburse us for a portion of certain expenses it incurs that are related to establishment and maintenance of the ADR program. There are limits on the amount of expenses for which the depositary will reimburse us, but the amount of reimbursement available to us is not related to the amounts of fees the depositary collects from investors. Further, the depositary has agreed to reimburse us certain fees payable to the depositary by holders of ADSs. Neither we nor the depositary can determine the exact amount to be made available to us because (i) the number of ADSs that will be issued and outstanding, (ii) the level of service fees to be charged to holders of ADSs and (iii) its reimbursable expenses related to the program are not known at this time.

Payment of Taxes

ADS holders will be responsible for any taxes or other governmental charges payable on their ADSs or on the deposited securities represented by any of their ADSs. The depositary may refuse to register any transfer of ADSs or allow a ADS holder to withdraw the deposited securities represented by his or her ADSs until those taxes or other charges are paid. It may apply payments owed to such ADS holder or sell deposited securities represented by such D ADS holder’s ADSs to pay any taxes owed and such ADS holder will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.

Reclassifications, Recapitalizations and Mergers

*If we:*		*Then:*
· Change the nominal or par value of our ordinary shares		The cash, ordinary shares or other securities received by the depositary will become deposited securities.

· Reclassify, split up or consolidate any of the deposited securities		Each ADS will automatically represent its equal share of new deposited securities.

· Distribute securities on the ordinary shares that are not distributed to you		The depositary may also deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. The depositary may also sell the new deposited securities and distribute the net proceeds if we are unable to assure the depositary that the distribution (a) does not require registration under the Securities Act or (b) is exempt from registration under the Securities Act.

· Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action		Any replacement securities received by the depositary shall be treated as newly deposited securities and either the existing ADSs or, if necessary, replacement ADSs distributed by the depositary will represent the replacement securities. The depositary may also sell the replacement securities and distribute the net proceeds if the replacement securities may not be lawfully distributed to all ADS holders.

Amendment and Termination

How may the deposit agreement be amended?

We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.

How may the deposit agreement be terminated?

The depositary will terminate the deposit agreement at our direction by mailing notice of termination to the ADS holders then outstanding at least 30 days prior to the date fixed in such notice for such termination. The depositary may also terminate the deposit agreement by mailing a notice of termination to us and the ADS holders if 60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment.

Table of Contents

After termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect distributions on the deposited securities, sell rights and other property, and deliver ordinary shares and other deposited securities upon cancellation of ADSs. Four months after termination, the depositary may sell any remaining deposited securities by public or private sale. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability for interest. The depositary’s only obligations will be to account for the money and other cash. After termination our only obligations under the deposit agreement will be to indemnify the depositary and to pay fees and expenses of the depositary that we agreed to pay and we will not have any obligations thereunder to current or former ADS holders.

Limitations on Obligations and Liability

Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs

The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:

are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;

are not liable if we or it exercises discretion permitted under the deposit agreement;

are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;

have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;

may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person;

are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and

the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding Depositary Shares or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit.

Requirements for Depositary Actions

Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of ordinary shares, the depositary may require:

satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and

compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.

The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.

Your Right to Receive the Ordinary Shares Underlying your Depositary Shares

ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:

when temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of ordinary shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our ordinary shares;

when you owe money to pay fees, taxes and similar charges; or

Table of Contents

when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.

This right of withdrawal may not be limited by any other provision of the deposit agreement.

Pre-release of Depositary Shares

The deposit agreement permits the depositary to deliver ADSs before deposit of the underlying ordinary shares. This is called a pre-release of the ADSs. The depositary may also deliver ordinary shares upon cancellation of pre-released ADSs (even if the ADSs are canceled before the pre-release transaction has been closed out). A pre-release is closed out as soon as the underlying ordinary shares are delivered to the depositary.

The depositary may receive ADSs instead of ordinary shares to close out a pre-release. The depositary may pre-release ADSs only under the following conditions: (1) before or at the time of the pre-release, the person to whom the pre-release is being made represents to the depositary in writing that it or its customer owns the ordinary shares or ADSs to be deposited; (2) the pre-release is fully collateralized with cash or other collateral that the depositary considers appropriate; and (3) the depositary must be able to close out the pre-release on not more than five business days’ notice. In addition, the depositary will limit the number of ADSs that may be outstanding at any time as a result of prerelease to 30% of the number of deposited shares, although the depositary may disregard this limit from time to time if it determines it is appropriate to do so.

Direct Registration System

In the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile, will apply to uncertificated ADSs upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the depositary may register the ownership of uncertificated ADSs and such ownership will be evidenced by periodic statements sent by the depositary to the registered holders of uncertificated ADSs. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer.

In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary’s reliance on and compliance with instructions received by the depositary through the DRS/Profile System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.

Shareholder Communications; Inspection of Register of Holders of Depositary Shares

The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.

Table of Contents

EXPENSES

The following is an estimate of the expenses (all of which are to be paid by us) that we may incur in connection with the securities being registered hereby, other than the SEC registration fee.

SEC registration fee	$	0
FINRA filing fee		4,250
Legal fees and expenses		(1	)
Accounting fees and expenses		(1	)
Printing expenses		(1	)
Miscellaneous expenses		(1	)

Total	$	(1	)

(1) These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time.

Table of Contents

LEGAL MATTERS

Unless the applicable prospectus supplement indicates otherwise, the validity of the warrants and units governed by U.S. law and certain other matters of U.S. law will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Unless the applicable prospectus supplement indicates otherwise, the validity of our ordinary shares underlying the ADSs and certain matters governed by English law will be passed on for us by Brown Rudnick LLP. Additional legal matters may be passed upon for any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement.

EXPERTS

The financial statements as of December 31, 2021, and for the each of the two years in the period then ended, incorporated by reference into this prospectus have been so incorporated in reliance on a report of Mazars LLP, an independent registered accounting firm, given on authority of said firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2021 contains an explanatory paragraph regarding our ability to continue as a going concern.

Mazars LLP, London, United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

The financial statements as of December 31, 2019 and for the year then ended, incorporated by reference in this Prospectus and in the Registration Statement have been so incorporated in reliance on the report of BDO LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2019 contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

BDO LLP, Reading, United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

ENFORCEMENT OF JUDGMENTS

We are a public limited company incorporated under the laws of England and Wales. Certain of our directors and executive officers and experts named in this prospectus reside outside of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may be difficult for an investor to serve process on us or our directors and executive officers or to compel any of them to appear in Court in the United States or to enforce judgments obtained in U.S. courts against them or us, including judgments based on civil liability provisions of the securities laws of the United States. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would be considered punitive in the United Kingdom if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a treaty providing for the mutual recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters.

WHERE YOU CAN FIND MORE INFORMATION

We are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we file Annual Reports and other information with the SEC. As a foreign private issuer, we are exempt from, among other things, the rules under the Exchange Act prescribing the furnishing and content of proxy statements and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

The SEC maintains a web site that contains reports and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is www.sec.gov.

This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement of which this prospectus forms a part. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC’s website, as provided above.

We also maintain a website at www.midatechpharma.com through which you can access our SEC filings. The information set forth on our website is not part of this prospectus.

Table of Contents

INCORPORATION OF DOCUMENTS BY REFERENCE

The SEC allows us to “incorporate by reference” information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We filed a registration statement on Form F-3 under the Securities Act of 1933, as amended, with the SEC with respect to the securities we may offer pursuant to this prospectus. This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities we may offer pursuant to this prospectus. Statements in this prospectus regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the registration statement, including the documents incorporated by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed above in “Where You Can Find More Information.” The documents we are incorporating by reference are:

our Annual Report on Form 20-F for the year ended December 31, 2021, filed with the SEC on April 26, 2022;

our Reports on Form 6-K furnished to the SEC on January 18, 2022, March 8, 2022, March 9, 2022, April 14, 2022, April 26, 2022, June 6, 2022, June 10, 2022, June 21, 2022, September 14, 2022 (both filings), and October 4, 2022, that we incorporate by reference into this prospectus; and

the description of ADSs representing our ordinary shares contained in our Registration Statement on Form 8-A originally filed with the SEC on December 2, 2015, and as amended on April 30, 2021, including any amendments or reports filed for the purpose of updating such description.

We are also incorporating by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and certain reports on Form 6-K that we furnish to the SEC after the date of this prospectus (if they state that they are incorporated by reference into this prospectus) prior to the termination of this offering. In all cases, you should rely on the later information over different information included in this prospectus or any accompanying prospectus supplement.

Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits are specifically incorporated by reference in this prospectus, will be provided at no cost to each person, including any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to:

Midatech Pharma PLC

1 Caspian Point

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

+44

29 2048 0180

You may also access these documents on our website, www.midatechpharma.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

You should rely only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.

Table of Contents

PROSPECTUS

May 26, 2023

You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with different information. You should not assume that the information contained in this prospectus is accurate as of any date other than the date of this prospectus. We are not making an offer of these securities in any state where the offer is not permitted.

GRAPHIC 2 biodexa_backpage.jpg GRAPHIC begin 644 biodexa_backpage.jpg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�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end GRAPHIC 3 biodexa_logo.jpg GRAPHIC begin 644 biodexa_logo.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0!F17AI9@ 34T *@ @ ! $: 4 M ! /@$; 4 ! 1@$H , ! ( $Q ( 0 3@ M !@ 0 & !<&%I;G0N;F5T(#4N,"XS /_; $, 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_ !$( &D MEP,!$@ "$0$#$0'_Q ? !!0$! 0$! 0 0(#! 4&!P@)"@O_ MQ "U$ " 0,# @0#!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q ? 0 # 0$! 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($ M! ,$!P4$! ! G< 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@ , P$ M A$#$0 _ /[^** "B@ HH ** "B@ KQK]H7XW>%OV( MQ6(FJ=&C35YU)RVC%=S'$XFAA*%3$XFK&C0HQYZM6;M"$;I7;]6E\SV4G'6O MDG]C']K;P+^W-^SCX3_:(^&.G>(O#_AKQJ-8M+/3_$]@^GZUIU[I&H7.E70G MMI %*K<0&6&1,QRQE2">:VS'+,?E&,J8#,\+5P6+I9]:*ZMD*P8@X.#G!] M#Z&O@']AG]FK]H?]GFX^/+_'?]H;4OCM;_$7XL^(/&?P_AU&U: ^!_"VI733 M6GAZ)V4;D@B9(Q&A,2!/D !-;9I@,'@5A?JF;X7-77HPJU5AJ.*I/"SDDW1J M?6*5-2G&[3=-R6G0RP6*Q&)=55\#6P:A*T)59TYJJM=8\C;5K;MM-?N;KX::BFI^&VT37M0T94G37_#? MB,"Z2SEC6X0ZCX6TT_."?*\Z/.).%EU+**JK_P!J8S&X248MX=87!T\4JDN2 M;2J.>)H.FG44(W2E:,I2^RDS%U,P@X?4L-AZZ;M4=>O*CRJ\+./+3GS+E<[N MZLTO=>S^QPRLH92"K %6'((;!!&.H((Q4,$$=K:P6L8(BMX(K>/<68A(8UC3 M+'+,0%&6.23R>:\Q[NUVKZ-JSMTNKNS\KOU9VJ]E?1V5^MGU^XG# ]#FOESX M3_!GXJ^!OCK^T#\2_%WQJUCQUX"^*5_XZ&KW2F[D9V.TG'%=N(PV'I87"5Z6/H8BMB%-U\)3I8B-7!\K2BJTZE*% M&HZBUC["=1)+WFGH)OJ_9QA4E5CR]?:0A MY7/J2O&/#GQT\&^)_C+XY^!NG1:ROC+X?^'-"\3ZY+<:5=P:,VG^()Y[>Q2Q MU22);2\N0]O(9X89&>%=I< &LIX/%4\/2QST5S&P44 %% !10 44 %% !10 M4A('4XH 6D!SR.E "T4 %-;.UL==IQ]<<4 <#\5M=\5^&?AIX]\0^!="'B?Q MGH?A'Q!JOA;PX9/*&MZ]8Z7=7.E:69/X1>WD4,&>^['>OQP_8Y\??\%7M<_X M*)_M'>&OVD_!=AI7['>F3:^/ACK TF&SMY88KK;X4;P]J:,T^JF[L]KZO]HR M+>5B$ YQ];B>')91E^79[6S'A_,J->I1J/*J&8^UQCC>,Y4<30@H3A'_ )=U MN2IS0N]MSYZAG4,QQ>+RNG@\VP=2G&K!8ZIA.3#II)*I2JRZ?\$N/CQ^U?\ M.]9_;G^ ^F?"_Q$/'VN>%]+\,7FG.+'Q/X0CMX M',][I&IQR!HH+Q[C3F,JM#=K )57!K]6@ .@ [\ #^7U/YUY^=YOA7=MW>IW9;E];!4*M'%9AB,S=6: MESXN%/W(J,8^SBH1LXMKF:E>S^&T=#G_ MX2\+^!]$L_#7@WP_H_A?P]IRN MEAHF@Z=:Z5I5DLDC2R"VL;**&WA$DKO(^R,;G8LV22:Z&O%J5*E63G5G.I.6 M\ZDI3D_64FV_FST8PC"*C",816T8148KT44E^ 45!044 %(2!UXH 6@'/2@" MNEI;1SR726\*W,J+'+<+$@GDC0DHDDH42.B$DJKL0I)( )JQ3N[)7=ELOZ]! M65[V5WN[:OYGBJ?%N];X\'X+?\(%XN%BOP]'CK_A9!L5'@EISJS:7_PBZZAO MW?V\% OC;[,&U)?(XKVAN 2 "1T_$_\ UZZ/:X?ZK['ZJOK/M>?ZW[:HY.G: MWLO8?P[7U4U[_2[5[X^SK?6'5>(;H>SY5AO9024[Q_>>UTGLFN3;5Z-V'5YK M\*O$_CCQ;X9FU3X@>!V^'^NIKFNV$6@OJ<.K-)I6GZG#G!5$E*4;5*52E*\79^Y5C"5NSM9JS6C/2J*P-0HH ** "B@ HH _)[ M_@MA\=/BM^SC_P $\/C-\6_@KXNN? WQ#\./H T;Q':6UK=SV2W>HK#!;_@E5^T"J@LS2>%PJ@9))U9< >Y/ ]R*_1/"O M"X7&\:99AL9AJ&*P]2&(]I1Q-*G6HR2I-KFIU8R@]4K76A\;QYB:^$XO\ @L)X:^ G[)_[,/[./[.WP%^*_P"V)\=/"GP"\#7?CG0OA%I<=UX<^'EU M=:5"UIIOBGQ!:,>MNN&1<3991R3*UC,Q]OC)8'#3K0 MIQK8O$)RI0]ZLJ$*LH.5TU[3E;W2MJ?U/5^$_P"Q;_P74^"O[1WQDM?V9OC? M\,OB!^RC^T/J$]O9:!X(^*=G%;6/BO4)RP2PT;5HOW,6H2LNRVLKPHUT_P L M$CN"M?-YEP9Q1E.'>,QF3XKZDM98W#.CC<)%;\T\3@ZM>E!>Y@N)< MCQ]=87#9A1>);LL/64\-6DW:T84\1&E*I)\R]V"D_(_3K]K[XP^./@9\$?$/ MQ"^'GA*3QEXETZYTZVM]-%OP6?^E26MFARXAYRZDD+DUS M_P"W5^UAX8_8E_9A^)'[2WB_PCK'CGP]\.[&SO+_ ,,Z#+8P:KJ4=[?6]FL= MM+J++9H4>59'\TD;5/&>GH>'6(PF&XKR^IC.#\+QU1<:T?\ 5W%XZKE]'%S< M+QG]9IRC%2HV&N95*F'E3XJRS M+L+FF)PL8UH.6'6%Q5DX8E>Y*K1J4:].R<*B3DGZ'^S3\2O%?Q?^#7@OX@>. M/"D_@WQ+K]A//J.ASQSP^2\-Y-;Q7,4-QB>.WO8HUNH%F D$4B[A4'[+OQYT M+]I;]GOX4_M :#H=_P"%-!^*7@W3_&.GZ'K$MJ^H:/8Z@C2):W\UHQLS+ B$ MRO"WE8&0<9K@XUKX7$\49M4P?#6'X1HO$\L>'L+BJ^-HY=*$(0G2CB<1.I.H MW)EX=Y5FN2\'9+EV=<98WC[,$="U:!R+O3KC7KF1(KV6T"M'QZ^(XHR M'#5GAYYC2J8B-U*CAHU<74BTTFI+#0JJ+3:O&3378_?.OP"^ /\ P7G^&NO? M&GPW^SC^U_\ ;XL?L8_%GQ5<#3]!?XIZ?;)X-U?5)Y=MG81Z]:R/%8/=+A( MIKS;;-.5C\Y=X(,5P/Q3A,-/&RRFMB,'35ZF*P%7#YC1@M-9SP-7$*,=?B=H M^8L/Q3D.(K1P\J>+_$6LV&C^&-%TNXUK5=ID]3!TJD>:G+,,1A,OYXVCJHXS$49V]Z*UBM917VE?YR?%_#L:KHQS*G7J M1=G'"TJ^)2:W]^C2G!VLV[2>D9=F?:W_ 78_:"^,/[,?_!.CXI_%WX%^,[K MP#\1-#USPA;:7XDL[6UO)[6WO]5$-Y&L-Y'+ PGA&PED)7.1R*_$7_@K'_P5 M2^'7[8O_ 3=_:(^ OC'X8_$G]FS]IKPO+X%\1:G\&?BYH_]F:EK&C0ZPHO= M4\)ZI"9+#6[:V+B2:"*475O 5DD0@DU]KX<<'9CA>,,M_M[)8ULMK4L5&-6K M3P^/RZK45)N"5>E+$85SNFXKGYM'IN?.\5\2X*MDTWE>9^SQ<,3A&Z<95<+B ME!UH*5Z56-*K*%Y14K1<'=7;31_3Q_P3U^(7C+XK_L4?LS?$?XA:U-XB\:^, MOA%X3U[Q+KD\44$VJ:M?6"2W=Y)# JPQO-(2Q6-509P !7$_\$N)HX?^"=_[ M(_X+C^&-1^+GC7X"?L-_LW?&']MGXD?#F]NM.\=Z MA\-M/M;3P+X;O[&Y:UN[5_$6I2PPZD\<\4T'F63&$S12*KLJAFK#\%<35Z%/ M%2RR>#PM5)TL1F5?"Y72JJ2YDZ4LPK8;VEXN_P"[4M-=F%;B;)*-65#Z]&O6 MA?GI8.G6QLX--1:FL+3K*+3=K2:UNMTS]ZNO!K\/_P!F/_@M;X!^)'QWT3]E MC]J'X&_%/]C?]H#Q'%&OA;PY\6+&T7P]XQOWW?Z#H7B"QEEM5N7^7[/#=,GV MALI'(6&&C'<'<29?A98ZMEE6K@8.T\;@JE#,,+#_ !UL#5Q$*:6S M-?AWX7TWP#XD\2:5XSOM4M-9\5:5&KZ/X+CT^"WGM[K7G8AHH-0>:2&V*9)D MA?(Y /P;_P %'/\ @I39_P#!.+3/A_XZ\?\ P)^(OQ"^#_B_6H=!\1?$GP-> M:+)8_#R_EN8$C?Q+I=[(E^;6:UDENK:>W#),UK/;@K*%#99%D&:9]'%T,JRN M.9XF$(R488NE2Q5!1;DYT<+/$TI8A37NNU*JM$HVD_>K-,UP65U,-/'8^>"H MSDUKAY3H5G+E2ISKJC45-INZ2G"3UW29^H=>5>$?C5\,_&_PDTSXY>'/%VE: MA\+]6$_$Q;>+EN(ETQ/#8T]M3GO[F4L!;BSM$D:\BEQ);O%)%(HD4BO$J8 M;$TL0\)5P]:GBHU%2EAITYQKJJVDJ;I-<_M&VDHVNVTDM3U(5Z%2C'$PK4Y8 M>4%55>,XNDZ;5^?G3<>6VK=]#U6OR?\ V!/^"J'A;_@HC\1OB_HWP5^#'C^S M^#WPCU:;0)OCKXCN]'M/"OBS6EED2VL?#6EQR/JMT]Q#"UZ\C*$MK.2VDG"- M'_&O[0_A']DG]K/]G3XL?L>?'SQX%7P5I?Q'M;*?PSXKNIQ M))966G:S83RI!<7D<4D=O]H'ERW2^1YBNRBJQO!G$F!PE3'U97&#%H^@Z=0+'DL51MH(.*_2_"2<(<(?$UE#?2M?ZGM>ZN8M.C=+"RADF M,=K! (HHXQN!_&#]AS_@HC^T-_P2X_9L^#/PB_;$_9Z^+_Q1^$'B'P'I7C3X M*_&7X=:!J&J3:%H.N1"ZE^&_CS2Y;:6;3-8\-3NUO:!WCD-JZYB**-OK<<<, M\29]Q'F6,R_%T^)(PM:$<7*5.+>(C7C3DJCF]91E+FIR]Q*R1Z]_ MP<\?!?P=H/P+^!?[7GAFRMO#7QJ^#7QE\*V>B>+M&@AT[7=0TW4]0MKA+"[U M&U$5U<+87=G]HL%9I#!-+OB+XR\?Z9=Z?+XGEM;ZTGEE?SK>TM;N\%E:?9]&TNW,S6LES- M'N!QW T*7@<)P[A:^.S"G7YO[2HX:I3H8>F[17/7JPI\\8S:J?R MPY>=-RLG^I'_ 5J\?:I\4_^"#7CCXCZW$\.K^-O@I\,_$NI1RC]ZM[JQT>[ MN/,_VVDD9VX'S,Q[U[1_P7%^'\NG?\$B_CY\/?A_X:U/5%T?P9X6T+P_X>\/ MZ=<:CJ#66EZGIUM;P6MC:1O/*8;>+)5$) 4G@#-?&>'F(PM;Q'P&(PU..$PE M7&8JI1I3<8QHTI4ZSA%MV4;)I6OOHNB/JN*Z.(I\'RP]:3KXF%/ PJSBFW4J M1J4E-V5^J;O\SR?P;\3/$GP=_P"#=W3_ (D^$+BXM/$OA;]BB2[T:\M)'AN; M.\NM)?3ENX)4^>*6W6\>5'3#*R#!'4?4/[#7P3LOC#_P2%^"7P&^(6E7^E6? MC_\ 9B@\#>(-,U2RDM=0TW^U]'N;'==65PJ20W%G-)'<^3*JMNB4' .1EF^/ MR_ ^*6,S#,*:Q&78?B%5\1%1512HQG!N2CM/ETE9/5+2YGE.#QN+\/\ #8+! MS=#&ULIC3HRDW3<:EI67-O#FMR\W2^NA\N?\&WWP$^'_ ,/_ /@G)\.?BQIV MEZ;?_$CXW:YXP\8^//&LUO#<^(=3NH/$FHZ/86%SJTJ/>M!8VFGQGR#-L^U3 M7$S R2,Q_-G]C_\ :N_:3_X(4S>+/V*/VJ?V>/BM\7/V?=%\8:[KOP8^./PU MT?4-9L5T7793=C3Y;>.VN+98KF[\Z\FL_/CO;*\N)U9&B(KZ;Q"R;.>,,W>> M<.XNCQ!DM>C06$P^#QM%U$,RR_A[+ M_P"S,YH5,JS.G5J2Q%:OA*D88OGG>G..(I0J0E:+4+.?*G%\K:9^FW_!QO\ M ;X??$7_ ()N?%3XF:MHVEP?$'X)7GA[Q_X$\8"V@@U[2K^SU6WMKFQL]51% MNX[?48)@LT*RX9H8G50Z@U^9G[8G[8'[2/\ P7(@\.?L1?LD?LZ?%7X6_ _Q M)XLT'6/C-\W%MYA+_8Q.UWJ,\448C$0)I>' MN1YWPEG-/.\_Q5'AS)J-&HL9'%XZ@IXZ+2Y,/'+Z5:=2M)M'OA!\+/%VOQ73)V8/G\-\2\+87Q-Q M.>UL/'#9/B*V*^IU)T[T\+6JJU/%NDT_9QF^=JT;TO:)J*LVNC.LCS[$<#X; M+*5:5;,J-/#/$TU).I7ITTE]73TC5=*\6X2?+6=*TI6:/1?^"5_[.'PJ_9Y_ M87_9L\/_ Z\+Z1IT\K3K+3;S3KAA/93*9/GB M5:CB_@SBS-\ZQV:X.I3XEP.-KU<1@\9@E3=*=>-6BX0M'V?(N M54WTB5PWQ'P_EN5X3 8F$\FQ>&I0I8FCBL'5HRG7C"*J5>>%.2G[27O'N)\-4S;'4,FPU>G6A_9=?,*$\3CY\ MJ:7U&E5J>R5+2HZ]=4^5)\EY-I>7QSF>69SE*IY?@JV:UJ>*P\OK5+#3ITL/ M'GM)?6:L*;E[9+V:A3YXR2O.T8Q;_7K6_BEXI^#7_!NWI_Q&\%W=WI_B;0_V M.?#,6EZA8DIT'P=K5CJ=E+;7^DW-WHJ"WDNK&=5ECFT^^CM[AK M>158M#L.">/C<=F&6Y=XI8S,,TIK$Y;A\_JU<1%)55*"J5+3Y5=5.1M3LKO9 MI7L>_A<%CL9P%A\%@92H8ZME%"G2DY.E*,U&FY1:]GN+?3F1+6>W-K.L@O8X(YQ=65Q<30S( M5&:^_P",:8=825ER\M M*A&-U9JZ/D^&ZJR?!_V?F6;8_(,;2D_;QJY9A/98B3>E2GB5A*CJIZI<]1V5 MN2ZU7!_\%0-7_P""A'_!1'PY\&I-$_X)B^/_ (._%3X+_%#1/'7ACXH+XHTO M5-8MM/M9X&U#08Y["TM[Z.UO);>TNF)F9(S;?(!O?/V);?\ !1/]O#_@I[^T M+\)OAY^P7\,_B/\ LO? 3P7XG@\1_&3X[_%#PNZ#Q)H5O+ )/#FFZ=?6T%N_ MVF)+E(;:&22Z=Y_/F CA KFR.MFO"6&Q^85>'C*,9[J/-)=68T\!G];"X:&:9SG=6G4=2%7!99A*2H: M1I\T\54P^'2B^92BU5Y>>"=TXQ4OZ!_%GP8\.?M+_LP1_"+]H3PO9ZW8_$3X M5Z1H_C[1=2MX;EK77-2\-VJ:I<0^,OB)^TK\=K.\\%> '\+:!J6HP>$#J*1Z1<>--5G ML+::&SFMI[Q?[+AF>(/=;IPRI;$C\LX8R7/<_P X>)R.45Y='#YG&6.Y\.J4,'[/ZQB,: MX0@M:<5R\TFTY5'RQC)MQ?-:+_DX\4?$/]I']G+Q;X\_X(0^#?VE/"U]$/B M/\=]%\+Z=\*QCFC:*'5]-2YCACUD36\6([ MN7/[Q_"/_@WW\$S_ /!-GQI$OBK=Q:K^V%\599/C'>?&B:(R>)O"?Q8:R74 M=#TBUUB1C?#3;"]S:ZH/M"I/>7-U>'THJ45?]Y_V/OV4/A)^QA\!/!'P(^#NB M6FE>&?"NFP)>7UO!#'>>)M=DMXAJOB75IDR]UJ&JW"-,[O))Y41BMXSY42 ? MDQ_P1,_;/^/7Q-\!^-OV-?VO?"/CCPK^T?\ LZO=>%K3Q?XHT;5;6S^(OA*P M\[3;#5K75KNW2WO=3TDVP29XYI!=V$EC=HQ8R$_D'&V1<09?F"Q^<8]9U0QT MU+#9W0Q/UK#UX2<&MIR>&:C)2^KVC%*ZIIQ/T;AC-,JQ.#>%R_"2RVKAHVJY M=6I^RK0E&T6[VM5YI)KVEVW:]3ED[' ^./VWO^"6O_!,+]HWXR>&?@'$_'/ MQ=_:I^+6M)KGQ4\+_ [0+GQKJ\VMF2\NVM]2UNYGDM-&NO.NI9+O3X'PNZ,S M*-BJ/RT_8@_:+O?^"._[47[9'@;]L+]EKXI^+_$7Q4^*^N>./!WQI\*^#+OQ M3/K'A^[U34KNRLK?5'L[E[C3)XKB*2(VMUNANA+%<)\@ _1L?PO1>2Y)4HPS MKQ$C+"PFG3X@IX? 9;)PA?#PPL(U\7'EOROFG"$5_*?'83/)_P!I9A2J2R_A M&4*G*E+**E;$XJ/,I.#?''Q,DM;;QYXON=7\5>&?M&E0P6<$36ND MVT6Z1 TT@=KF4%%!;-W_ (*5_&7]LS]NKQ#\ /VZO#G[*?Q9\*?L;?LS_%WP ME=>&? VHZ+>M\3_&5U9Z_INM>(/'UQX6@MA<6NB26U@FDZ;=F!H(##O=_P!Y M(:^DX*P^&P. XBRVIEF3):H3C&I6I8C&5:-&+G/DI M^[3JS;NX\L4UX'%-3$XS'9+BZ>-S/-\/@\;1>(S".6QPF"HIU:,W3A*GAHU) M^[&\[S:BU%1UDTO[L4&% R3C/+%O%7@ MK2?B#I-QJEKX7\;:=)I7B?1_LVHWFFRVNJV$J(\$PFLY'3*CS('BD'#@G^9< M;@L5EN*K8+&T98?%8>2C6HS<7*G)Q4DI.$I1ORR3T;WUU/W+"XJAC:%/$X6H MJM"HKTZB4DI*+Y=%)*6C3B[K=,]XNK.UOH6MKVV@N[=\;X;B))HFQTW1R!E/ MXBK-DQ>1I>G66G MP[M_E65M#;1[L ;MD*(N< #IT ]*T*3E*3O)N3[MMO\ $$E'2*279)+\BK>V MEM>VTMO=V\-U ZG?!/&LL3\9 >-PR,,CHP(JU0FUJFT^C6C7H#2>C2?JD_P= MU]YY?$_$GBCQ/X=O[OQ7X!G^'-[8>)O$NBV&A37UI?_ &O0](U6:RT?7H9+ M)5B@@URQCBOX;4@26ZR^6_S UI?$WQW'\-?!6K^,Y="USQ*FD?8]VB^&[-K_ M %F\^V7UO9 6=JO,AA-P)Y>R01R.?NUUN,L?B(0PN%A2J2A&"I4ZE1QG*$?> MJ2EB*LVI3M=^^H)V48Q6AS)QP="4L1B)U(1FY>TJ0BG&,VE&FHT:<5RQVC[K MEUDWN=9?Z/I.JQK%J>FV.H1J=RI>VL-TBG&,A9D< X[CI5NVF,\$4VUD\U$D M".,.H=%;:P[,N<,#R""*Y4YP;LY1:=G9V>GH^YTVC))V4E9-75]TFMUVL_N* MFGZ-I.DHT>EZ98ZXGB*EDM#AYT6\+.&'Y\;[6G4JOV= M;%YAE^&HN+@HWJU.5N:;DG:,OP/Q7\9,7X=\5<&<+8+@W$<2XGC!8I4L71J8 MWV>7O#5\+2M5PN6Y/F^.Q/,JTIJ.&HN=H?#R\TH_:/\ PL/X8)XYM_@XPTV/ M5KGPPGBVUT\VUJFC3Z.UX;..2"0@6DLS3ABD:*Q(5F!K\ZY_V,OBMJ<$%]JL MU@^L:9\-KK3?";0ZK?>9X3UVZ^(">(K+2+2\,@N+JRT709)=.@GG=R^W!RN, M_0PX(\-/[/EAJWB'26=SSZ.$H9G2A3JX&EELLL^M2GCL(\1!T_8XU/ SQF#Q MV-H3J6 M9E'!U56]OELXYK2R['Y9EN*AA^?ZQ*C4@X'ZQ6][H\#2Z?;7.GPFPB'FVD4] MNAM80/EWP(X,,8']Y$49]Z_,'5?V:_C]J/Q#\9^(X+NPT^WU_P *>+O#\T]G MJ=Y&FJKJND:1;:/(E2>+QN"PN%KX; 5*53 >RIK,)UJE'#XC#5 M\4E4HRBZ3NC]+-2/A'5%ACU8>']03EK=;]K"Y4G:2QB2"^T&^N)OB+-N$_S/JT$OEB1LM(N M58D".!:\Y1J>)=+!J6+SNA1E+*J?\'**<*F'Q5=+-DJ<,X;E3R^$95' M*%YCK%\M_H%C=^(;"_P!( MMX;@S;A9C3X)XY(LN0Q"C"'!VP?AYP=C<14]KXGY1A\++ X3$T*^)P\%7A7Q M.&E7J83%X9X]NG/#U(K#UI8>KB%&I.+>B:.;,O&;Q+R[!T72\"N(L;F,,TS# M XS"X/'59X6IAL%C:6%I9AEV-64VJT<90G+&8>&,H8.,,75PKYFA0,-X;"@$;NV1^<-G^S7\:O[9^(L M$TU@FO>(+3Q++I?Q@&O:F->8:O9P)8:1+I*R?8$@M6CDLR5A79%B:,^823Y\ MN".%Z>'RR:\0\K PDL7668YFL+1IU[.C%^\_.RSQG\0JN P68YOX(\48"A5SNGE MN-^J8C$8[$X/"5,$L2L>LN>4X?,:\:6)M@:OLD'Q/9^';GQ/8/+P#EB".QK\ M]- _9'^*^DVVB:O>-+_ ."WC;P+XBULZG>M?B!2QV*PW$N79?B:E+ZKAMB*D<-5=3#U9PC4Y9)-4G%J1YC\5O&7&*&+I^$&)R?!8[@K.,XP5 M#$+'9AGF&XFP&-J4,)DV.I4\+AL'0>/PL:6,H4JLH2FJG)[93C*F?I<__"&> M)/L%Q?V6B7MU=V$%_:0:I#9/J"6=S$MPC?9KE3<1*$<&0;0J-D$\9K\_++]G MCXRZ7XIU>]N-.T3Q/JUUID5WHOC_ %77-3@O=&6'PA:Z(GA'^S8)5MIM/74( M9I=[H1)'<&1F\Q:\FKP5PQ'"PQ&$X_R^<\1B:M.-."P\*.$C_:$L-2I8IXC, M<+F%2?U2,,5+$T,KJ8/EG!>V^-P^APWBGQZ\=4PF/\),ZI0PF#HUI59O&U<5 MF$O[(HXVM7P/U')\=DM.F\9.6!AA,5GE#,%5IU+X96IQG]P^)_B'\/\ PE_P MA^BZD]E);>-O$MOX,T.VL8H+JQ?59X9YX[698=T$$2Q6\I8L %Q@CDU^>/@G M]E;XTP:;I]MKPTZVBA^)VC>,Q8Q:I=/'I]K%X1U#1M873Y"\DEF\^HSI- 86 MW!&$G$BU[$^!> ,OGF$<3Q]@LUG/(,3B11AQ9@\!G.&S*EB<5'&\- M8C*ZV,J8W"5I87 U=3"XN%.HW*%.LK'ZHZ6^E&W\K238_9K=F MB$5@T)@A8-EX]D!V1L&.64A3DY[FOD[]D/X4>/\ X3:/XXTGQI]G6QU#Q(+W MPY']NGU+419"W1)WU"^G=VG:2?+0L<-L^^,U\+QGPYDW#U?+XY+Q1A.)J6,P MOMZU3#TX4JN#JJ2C[#$4Z>)Q<(SM:2M6EH[;IGZOX:<:<3<8X7-JG$W F8<# M8C+<>\)AZ&,KU<11S&CR1G]9P=6M@MOL.BOBS]-"B@ M HH ** $958890P]& (_(\4M 'D7QTUOXK^'/A=XJUCX(^$]%\:_$RRM[1O" M_AKQ!J+Z5I.IW#WUM'=)=WT2N\"Q6;W$R$*=SQJIP#FO7:Z,+7CAZ].M/#T, M5&#;=#$*HZ,]+6FJ52E/3=MXF M-X>N-7N=!T:Y\06<&G:Y/I6GS:Q8VLIGMK/5);6)[^UMYC\TL,%TTD44C %T M4,>M;!&01QTQTXK&[LO1&+HOB3P_XC6^?0-9TW64TS4+G2=1;3;R"\%CJ=D_EW=A= M&!W\B[MG^6:"3;)&W#**\B^!7[.OP[_9XM?B#:?#RVU"VB^)?Q&\2_%'Q,+_ M %"YU R^*/%=U]KU66V-S(YMK5I<>3;1;8HE&%'IUXR&!INA]1Q&(Q"E0A+$ M.O0C0]GB&E[2G34:M7VE.,KJ-27(Y)7Y$<^&EBI*K]:I4J5JC5'V5653FI=) M5$X1Y)M_93DK:W6R]MFLK.:>*ZGMX)9[?/DS21(\L.>OE.07CSWVD9[UX1^U M+X)^,?Q$^ OQ.\'? +X@Q?"[XNZ_X9N-/\"^.9[7[9#X M.?L_^%OB9X-^"?PU\)?&7QA%X_\ BCH7@[1]+\=>-+>W-K%XC\16]JJ:EJL< M'_+/[1-N;T)^;'.*SQ5&&'Q-:A3Q-+%TZ51TXXJ@JGL:T5:U2E[6%.IROIS0 MB]#6A4G5HTZDZ4Z$YQ4I4:G+SP;2TER2G&_HVUU2>AZ'HWBSPOXAO-6L-!U_ M1]7OM O3I^MVFG7UM=W&DWRJKFTOXH7=[6X"LI\N8(W(XK\[/V(?^"<>E_L9 M_&?]J#XO67Q;\-E[M[ZV7#@,1F5>OB(8[+X8.C3DUAZT<3"NZT>:R;A&*E"\;2]ZVONN M*M=^3_\ !2KPW_P4]UOXR_LK7'["?B30M$^&%CXL=OCK;W\MM#+<:;]NT]@] M^LZ.]UI7]F"]C6"WQ)]J96/8U^QF!Z#\JUR7B*>2X?'8>&59+CUCH+:ZC(U;RX_-"F0(GF$#@OM&_'MNSBI*^=>N_P#7]=.QZVRMZ;Z[ M=_S]1, =A^5+0 F!Z#\J6@!,#T'Y4M ";1Z#\J6C_A@$P/0?E2T &,=!^E% M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% %!10!_]D! end GRAPHIC 4 mp_logo2.jpg GRAPHIC begin 644 mp_logo2.jpg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end GRAPHIC 5 pipeline.jpg GRAPHIC begin 644 pipeline.jpg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end